var title_f40_11_41136="MRI cerebellar hemangioblastoma";
var content_f40_11_41136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cerebellar hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gadolinium-enhanced T1-weighted images of a cystic hemangioblastoma in the right cerebellum.",
"    <br>",
"     (Left panel) Axial image.",
"     <br>",
"      (Right panel) Coronal image.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Eric T Wong, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41136=[""].join("\n");
var outline_f40_11_41136=null;
var title_f40_11_41137="Arcuate uterus HSG";
var content_f40_11_41137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram of arcuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Barbieri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41137=[""].join("\n");
var outline_f40_11_41137=null;
var title_f40_11_41138="Collagenase (topical): Drug information";
var content_f40_11_41138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Collagenase (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31843?source=see_link\">",
"    see \"Collagenase (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Santyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13259795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Santyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme, Topical Debridement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dermal ulcers, burns: Topical: Apply once daily (or more frequently if the dressing becomes soiled).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Santyl&reg;: 250 units/g (30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Clean target area of all interfering agents listed above. If infection is persistent, apply powdered antibiotic first. Do not introduce into major body cavities. Monitor debilitated patients for systemic bacterial infections.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes debridement of necrotic tissue in dermal ulcers and severe burns",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9916496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Topical collagenase formulation (Santyl&reg;) may be confused with the injectable collagenase clostridium histolyticum (Xiaflex&reg;)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, pain and burning may occur at site of application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to collagenase or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Monitor debilitated patients for systemic bacterial infections because debriding enzymes may increase the risk of bacteremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For external use only; avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if systemic absorption occurs following topical application.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F154624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Santyl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 units/g (30 g): $212.30",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Iruxol (BR, VE);",
"     </li>",
"     <li>",
"      Iruxol Mono (BE, BR, CH, CZ, FI, GR, ZA);",
"     </li>",
"     <li>",
"      Iruxol Simplex (CO, EC, PE);",
"     </li>",
"     <li>",
"      Kollagenase (BR);",
"     </li>",
"     <li>",
"      Noruxol (IT);",
"     </li>",
"     <li>",
"      Novuxol (NL, TR);",
"     </li>",
"     <li>",
"      Salutyl (IN);",
"     </li>",
"     <li>",
"      Ulcerase (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Collagenase is an enzyme derived from the fermentation of",
"     <i>",
"      Clostridium histolyticum",
"     </i>",
"     and differs from other proteolytic enzymes in that its enzymatic action has a high specificity for native and denatured collagen. Collagenase will not attack collagen in healthy tissue or newly formed granulation tissue. In addition, it does not act on fat, fibrin, keratin, or muscle.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chamberlain TM, Cali TS, Cuzzell J, et al, &ldquo;Assessment and Management of Pressure Sores in Long-Term Care Facilities,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1992, 7(12)1328-40.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9296 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41138=[""].join("\n");
var outline_f40_11_41138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154628\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13259795\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154644\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154631\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154639\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154632\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154617\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154604\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154620\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154619\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916496\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154642\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154622\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154608\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299091\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154613\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862696\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154634\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154624\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539835\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154607\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/29/5588?source=related_link\">",
"      Collagenase (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/53/6996?source=related_link\">",
"      Collagenase (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31843?source=related_link\">",
"      Collagenase (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41139="Dyphylline: Drug information";
var content_f40_11_41139=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dyphylline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/25/17812?source=see_link\">",
"    see \"Dyphylline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lufyllin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase Enzyme Inhibitor, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bronchoconstriction (asthma, COPD):",
"     </b>",
"     Oral: Up to 15 mg/kg 4 times daily, individualize dosage",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; primarily undergoes renal elimination and an increase in systemic exposure is likely. The following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lufyllin&reg;: 200 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator in reversible airway obstruction due to asthma, chronic bronchitis, or emphysema",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Reactions reported with other xanthine derivatives and may be dose related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Circulatory failure, extrasystoles, flushing, hypotension, palpitation, tachycardia, ventricular arrhythmias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Agitation, headache, hyperexcitability, insomnia, irritability, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: SIADH, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, epigastric pain, hematemesis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Albuminuria, diuresis, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Tachypnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dyphylline, xanthine compounds, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3901332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease including, acute myocardial injury, hypertension, and heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patient with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Status asthmaticus: Xanthine derivatives, including dyphylline, are not indicated for the management of status asthmaticus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3901328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3901330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3901331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk concentrations are ~2 times the maternal serum concentration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F163968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lufyllin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $521.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $765.42",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diprophylline (RU);",
"     </li>",
"     <li>",
"      Dydilene (KP);",
"     </li>",
"     <li>",
"      Neophyllin-M (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3901339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes bronchodilatation, through phosphodiesterase inhibition which increases concentrations of cyclic adenine monophosphate (cAMP) and produces relaxation of bronchial smooth muscle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3901341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Not converted to free theophylline",
"     <i>",
"      in vivo",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~2 hours (may be increased in renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (88% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 108.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8908 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41139=[""].join("\n");
var outline_f40_11_41139=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163984\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163976\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163977\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163978\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804936\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163963\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163952\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163964\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163982\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163967\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901332\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299245\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163958\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163959\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901328\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901330\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901331\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163968\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163970\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901339\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3901341\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/25/17812?source=related_link\">",
"      Dyphylline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41140="Donepezil: Patient drug information";
var content_f40_11_41140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Donepezil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     see \"Donepezil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aricept&reg;;",
"     </li>",
"     <li>",
"      Aricept&reg; ODT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aricept&reg;;",
"     </li>",
"     <li>",
"      Aricept&reg; RDT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691710",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Alzheimer's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to donepezil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Do not swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12393 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41140=[""].join("\n");
var outline_f40_11_41140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162577\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022989\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022988\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022993\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022994\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022996\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022991\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022992\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022997\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022998\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=related_link\">",
"      Donepezil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41141="Isosorbide dinitrate and hydralazine: Drug information";
var content_f40_11_41141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isosorbide dinitrate and hydralazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/2/10277?source=see_link\">",
"    see \"Isosorbide dinitrate and hydralazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BiDil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F786635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F786662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 1 tablet 3 times/day; may titrate to a maximum dose of 2 tablets 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1623481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F786663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     If patient experiences intolerable side effects, dose may be reduced to as little as one-half tablet 3 times/day; dose should be titrated upward as soon as tolerated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12960381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BiDil&reg;: Isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F786633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F786637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Treatment of heart failure, adjunct to standard therapy, in self-identified African-Americans",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F786647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The following events were reported in the A-HeFT Study using the combination isosorbide dinitrate/hydralazine product. See individual drug monographs for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (50%), dizziness (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension (8%), palpitation (4%), ventricular tachycardia (4%), tachycardia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Malaise (1%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia (1%), angioedema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (4%), hyperlipidemia (3%), hypercholesterolemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), vomiting (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Cholecystitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (4%), arthralgia (1%), myalgia (1%), tendon disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Amblyopia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Bronchitis (8%), sinusitis (4%), rhinitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (1%), diaphoresis (1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F786642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to organic nitrates; concurrent use with phosphodiesterase-5 inhibitors (sildenafil, tadalafil, or vardenafil)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F786643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-induced lupus-like syndrome: Hydralazine may cause a drug-induced lupus-like syndrome (more likely on larger doses, longer duration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/sodium retention: Hydralazine-induced fluid and sodium retention may require addition or increased dosage of diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Use with caution in volume depletion and moderate hypotension, and use with extreme caution with inferior wall MI and suspected right ventricular infarctions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intracranial pressure increased: Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Peripheral neuritis: Hydralazine has been associated with peripheral neuritis (eg, paresthesia, numbness, and tingling), possibly due to an antipyridoxine effect. Pyridoxine therapy should be initiated with onset of such symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease (CAD); tachycardia, due to hydralazine, may increase myocardial oxygen demand.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (Gersh, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary hypertension: Use with caution in pulmonary hypertension; may cause hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (Trujillo, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: When nitrates are used in combination with hydralazine for HF, tolerance to nitrate therapy is less of a concern (Gogia, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F786652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F786651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis.  Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F786638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F786639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F786640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F786641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (BiDil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-37.5 mg (180): $461.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F786664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Blood pressure (standing and sitting/supine), heart rate; CBC and antinuclear antibody (ANA) titers (if symptoms of systemic lupus erythematosus occur)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F786656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hydralazine: Direct vasodilation of arterioles (with little effect on veins) resulting in decreased systemic resistance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Isosorbide Dinitrate: Stimulation of intracellular cyclic-GMP results in vascular smooth muscle relaxation of both arterial and venous vasculature with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload. Additionally, coronary artery dilation improves collateral flow to ischemic regions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F786658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     The following values are from administration of isosorbide dinitrate 40 mg and hydralazine 75 mg in healthy adults. Also see individual drug monographs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Half-life elimination: Hydralazine: 4 hours; Isosorbide dinitrate: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Time to peak, plasma: 1 hour (both agents)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Archibald DG, Francis GS, et al, \"Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure: Results of a Veterans Administration Cooperative Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 314 (24):1547-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/3520315/pubmed\" id=\"3520315\" target=\"_blank\">",
"        3520315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Johnson G, Ziesche S, et al, &ldquo;A Comparison of Enalapril With Hydralazine &ndash; Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(5):303-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/2057035/pubmed\" id=\"2057035\" target=\"_blank\">",
"        2057035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gogia H, Mehra A, Parikh S, et al, &ldquo;Prevention of Tolerance to Hemodynamic Effects of Nitrates With Concomitant Use of Hydralazine in Patients With Chronic Heart Failure,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 26(7):1575-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/7594088/pubmed\" id=\"7594088\" target=\"_blank\">",
"        7594088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AL, Ziesche S, Yancy C, et al, &ldquo;Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(20):2049-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/15533851/pubmed\" id=\"15533851\" target=\"_blank\">",
"        15533851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo TC and Dobesh PP, &ldquo;Traditional Management of Chronic Stable Angina,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(12):1677-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/11/41141/abstract-text/18041888/pubmed\" id=\"18041888\" target=\"_blank\">",
"        18041888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9014 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41141=[""].join("\n");
var outline_f40_11_41141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786631\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786635\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786662\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623481\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160050\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160051\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786663\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12960381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786633\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786637\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786647\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786642\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786643\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786652\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786651\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786638\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786639\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786640\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786641\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570490\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786664\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786656\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786658\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9014\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9014|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/2/10277?source=related_link\">",
"      Isosorbide dinitrate and hydralazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41142="Specialized revascularization devices in the management of coronary heart disease";
var content_f40_11_41142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specialized revascularization devices in the management of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41142/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/11/41142/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of coronary heart disease (CHD) has evolved significantly due in part to improvement in both surgical and percutaneous revascularization techniques. While the majority of patients with chronic stable angina are treated with medical therapy, revascularization on top of medical therapy is the preferred treatment strategy in many clinical subgroups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients who undergo revascularization receive percutaneous coronary intervention (PCI) with stenting, as opposed to coronary artery bypass graft surgery (CABG). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who undergo PCI receive stents. Specialized revascularization devices such as rotational atherectomy (for severely calcified lesions) or laser angioplasty (for in-stent restenosis) have been evaluated in clinical trials.",
"   </p>",
"   <p>",
"    Neither short- nor long-term benefits have been shown consistently with these revascularization devices. In particular, atherectomy devices have generally failed to improve patient survival or the durability of the revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These findings indicate that",
"    <strong>",
"     ROUTINE",
"    </strong>",
"    use of specialized device therapies (over the combination of balloon dilation and stent implantation) is not justified.",
"   </p>",
"   <p>",
"    The use and efficacy of rotational atherectomy, cutting balloon atherectomy, and excimer laser angioplasty will be reviewed here. The complications associated with their use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27108?source=see_link\">",
"     \"Coronary complications of atheroablative devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purpose of this topic, a specialized revascularization device is a catheter-based tool designed to address unique problems associated with certain lesions, such as those that are calcified. These devices have specialized functions used at the time of percutaneous coronary intervention and typically supplement or assist balloon angioplasty and the implantation of a stent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROTATIONAL ATHERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational atherectomy is performed with a rapidly rotating olive-shaped burr whose leading hemisphere is coated with microscopic diamond chips. Contact of the burr with fibrocalcific plaque grinds calcified atheroma into particles small enough to pass through the distal myocardial capillary bed. It was designed to both \"debulk a lesion\" and to remove calcified tissue that after might interfere with the ability of a percutaneous balloon to pass.",
"   </p>",
"   <p>",
"    The routine use of rotational atherectomy during PCI was shown to not be useful in a meta-analysis of 16 device trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/1\">",
"     1",
"    </a>",
"    ]. Using data from the four trials which evaluated rotational atherectomy, its routine use, compared to PTCA alone, was associated with significant increases in restenosis (odds ratio [OR] 1.25), myocardial infarction at 30 days (OR 2.18), and major adverse cardiac events at one year (OR 1.52).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Calcified and complex lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these shortcomings, rotational atherectomy is valuable for heavily calcified lesions that cannot be treated successfully by balloon angioplasty or that interfere with a delivery of a stent to a more distal location. It is also used commonly for calcified ostial lesions of the right coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/3\">",
"     3",
"    </a>",
"    ]. Uncontrolled results from a multicenter registry found that rotational atherectomy was successful (defined as less than 50 percent residual stenosis) in 94 percent of calcific lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Ostial lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Use prior to stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no value in performing rotational atherectomy",
"    <strong>",
"     ROUTINELY",
"    </strong>",
"    before stenting. However, rotational atherectomy has been used prior to stenting when a proximal calcified segment prevents stent delivery or when there is a large plaque burden, which may interfere with optimal stent expansion and may be associated with an increased risk of in-stent restenosis.",
"   </p>",
"   <p>",
"    One study described the outcome of stenting in 75 patients who first underwent rotational atherectomy because of calcified or complex lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/5\">",
"     5",
"    </a>",
"    ]. Procedural success was achieved in 93 percent of patients and 93 percent of lesions. Acute stent thrombosis occurred in 2 percent of lesions and subacute thrombosis in 1 percent. Angiography was repeated at five months and the restenosis rate was 23 percent. After six month follow-up, target lesion revascularization was required for 18 percent of lesions, one patient died, one patient had a Q wave myocardial infarction, and three patients required CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Internal mammary artery graft stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, stenosis within an internal mammary artery graft may cause recurrent ischemia after CABG. While such lesions are most often treated with balloon angioplasty, unsatisfactory results may occur when the lesion at the anastomotic site is rigid and fibrotic. Although data are limited to a small number of patients, rotational atherectomy may infrequently be needed for such lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H15134962#H15134962\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Internal mammary versus saphenous vein grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Saphenous vein graft lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increased risk for distal embolization, we generally limit use of rotational atherectomy in saphenous vein grafts to special circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use in diabetic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetics who undergo rotational atherectomy for diffuse coronary disease have a higher rate of angiographic restenosis at six months (72 versus 45 percent for patients without diabetes) and a higher rate of target lesion revascularization (67 versus 36 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     In-stent restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational atherectomy has been used to treat diffuse in-stent restenosis, particularly when there is significant hyperplasia inside the stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. It leads to acute lumen gain by removing plaque and intimal hyperplasia, while adjunctive PTCA produces additional lumen gain by further stent expansion and tissue extrusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/10\">",
"     10",
"    </a>",
"    ]. Despite success reported from a retrospective, observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/8\">",
"     8",
"    </a>",
"    ], a later randomized trial of 298 patients showed higher risk for recurrent restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not generally use rotational atherectomy for treatment of instent restenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of rotational atherectomy include severe coronary spasm, dissection, perforation, and slow flow through the capillary bed due to excessive particle embolization. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27108?source=see_link&amp;anchor=H4#H4\">",
"     \"Coronary complications of atheroablative devices\", section on 'Rotational atherectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjunctive therapy with abciximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal particulate embolization may combine with platelet activation and aggregation to worsen coronary artery hypoperfusion and precipitate non-ST elevation myocardial infarction. This mechanism is supported by a trial in which 100 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or placebo during atherectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients treated with abciximab were less likely to have elevated levels of CK-MB (8 versus 22 percent for placebo), slow-flow, or postprocedural chest pain.",
"   </p>",
"   <p>",
"    Further support for efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    comes from an observational study of 75 patients who underwent radionuclide myocardial perfusion imaging prior to, during, and two days after atherectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/13\">",
"     13",
"    </a>",
"    ]. The 30 patients who received abciximab during the procedure had a significantly lower rate of transient perfusion defects (33 versus 87 percent).",
"   </p>",
"   <p>",
"    Some of our experts use a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in this setting on a regular basis, while others do not. For those who do, any agent is acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rotational atherectomy summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update for PCI concluded that there is no evidence that rotational atherectomy improves late outcomes in lesions that can be safely treated with stenting or angioplasty alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. When rotational atherectomy is being considered, the weight of evidence or opinion was in favor of the efficacy of IVUS for establishing the presence and distribution and coronary calcium. However, in our practices, IVUS is rarely used for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIRECTIONAL CORONARY ATHERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The directional atherocath is a metallic cylinder with a longitudinal window in a cylinder that permits a circular cutting blade to excise tissue into a chamber in the catheter, which can then be removed. It has been used as a debulking device, mainly before the widespread use of stenting.",
"   </p>",
"   <p>",
"    It neither facilitates stent placement nor improves long-term outcomes after stenting. It is no longer in use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CUTTING BALLOON ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutting balloon is a device with three to four longitudinal atherotome blades mounted on the outer surface of the balloon. It produces sharp, clean, longitudinal incisions, leaving the interincisional segments of the untreated segment intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/16\">",
"     16",
"    </a>",
"    ]. It was proposed that this type of controlled dilatation might reduce the force needed to dilate an obstructive lesion.",
"   </p>",
"   <p>",
"    An initial nonrandomized matched comparison suggested that the incidence of restenosis and target vessel revascularization was lower with cutting balloon angioplasty than with other methods of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/17\">",
"     17",
"    </a>",
"    ]. This was not confirmed in the RESCUT trial that compared the cutting balloon to conventional angioplasty in 428 patients with in-stent restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/18\">",
"     18",
"    </a>",
"    ] or in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some operators favor the cutting balloon, which is less likely than a traditional balloon to slip out of the lesion, for use in ostial lesions, to reduce elastic vessel recoil, and for in-stent restenosis.",
"   </p>",
"   <p>",
"    The 2005 ESC Task Force for PCI concluded that the weight of evidence or opinion is in favor of efficacy of cutting balloon angioplasty for avoiding slipping-induced vessel trauma during PCI of in-stent restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EXCIMER LASER ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excimer laser has not achieved wide acceptance and its final role remains to be defined. It produces monochromatic light energy to cause ablation of plaque and, via the generation of heat and shock waves, plaque disruption. The lumen produced by the laser is 1.4 to 2.0 mm in diameter; as a result, laser angioplasty must be followed by the use of another device to achieve a satisfactory final result. Use of the excimer laser has been complicated by relatively high rates of coronary dissection and perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the meta-analysis of 16 device trials cited above, three trials evaluated laser angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/1\">",
"     1",
"    </a>",
"    ]. Laser therapy was associated with a significant increase in restenosis compared to PTCA (odds ratio [OR] 1.55), a trend toward an increase in the rate of myocardial infarction at 30 days (OR 1.39), and a significant increase in major adverse cardiac events at one year (OR 1.32).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy for in-stent restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excimer laser coronary angiography (ELCA) followed by adjunct PTCA has been evaluated for treatment of in-stent restenosis, although repeat stenting with drug-eluting stents is the recommended approach in most patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ELCA is associated with a high rate of procedural success and a low rate of periprocedural complications in patients with in-stent restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/21\">",
"     21",
"    </a>",
"    ]. Data supporting long-term efficacy come from observational studies comparing ELCA and PTCA to PTCA alone. The relevant studies show a tendency for less frequent need for repeat target vessel revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/22\">",
"     22",
"    </a>",
"    ], similar rates or revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/23\">",
"     23",
"    </a>",
"    ], or higher rates of recurrent stenosis and reintervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update concluded that there is no evidence that ELCA improves late outcomes in lesions that can be safely treated with stenting or angioplasty alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41142/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EXTRACTION THROMBECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several devices that can mechanically aspirate thrombus are available, including the Transluminal Extraction Catheter (TEC), the AngioJet, and the X-Sizer. These devices have been studied for their use in saphenous vein grafts and before primary PCI. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Thrombolysis and thrombectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H8#H8\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specialized revascularization device is an uncommonly needed tool with specialized functions that can be used at the time of percutaneous coronary intervention (generally before the stent is placed) that either allows for optimal placement of a stent or improved outcomes.",
"   </p>",
"   <p>",
"    Neither short- nor long-term benefits have been shown consistently with these revascularization devices. In particular, atherectomy devices have generally failed to improve patient survival or the durability of the revascularization. These findings indicate that",
"    <strong>",
"     ROUTINE",
"    </strong>",
"    use of specialized device therapies (over the combination of balloon dilation and stent implantation) is not justified.",
"   </p>",
"   <p>",
"    The following summarizes the current use of these devices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotational atherectomy may be used prior to stenting when a proximal calcified segment prevents stent delivery or when there is a large plaque burden, which may interfere with optimal stent expansion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rotational atherectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although, conceptually directional coronary atherectomy (DCA) offers advantages for the treatment of certain lesion types, notably debulking of bifurcation lesions, it neither facilitates stent placement nor improves long term after stenting, and requires high level of operator expertise for safe use. It is no longer in use. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Directional coronary atherectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutting balloon angioplasty can be used to avoid slipping-induced vessel trauma during PCI of in-stent restenosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cutting balloon angioplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that excimer laser angioplasty improves late outcomes in lesions that can be safely treated with stenting or angioplasty alone. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Excimer laser angioplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several devices that can mechanically aspirate thrombus are available. These devices have been studied for their use in saphenous vein grafts and before primary PCI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H23#H23\">",
"       \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Thrombolysis and thrombectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H8#H8\">",
"       \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8495455\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. David Williams for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/1\">",
"      Bittl JA, Chew DP, Topol EJ, et al. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. J Am Coll Cardiol 2004; 43:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/2\">",
"      King SB 3rd, Yeh W, Holubkov R, et al. Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA and NACI registries. J Am Coll Cardiol 1998; 31:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/3\">",
"      Motwani JG, Raymond RE, Franco I, et al. Effectiveness of rotational atherectomy of right coronary artery ostial stenosis. Am J Cardiol 2000; 85:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/4\">",
"      MacIsaac AI, Bass TA, Buchbinder M, et al. High speed rotational atherectomy: outcome in calcified and noncalcified coronary artery lesions. J Am Coll Cardiol 1995; 26:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/5\">",
"      Moussa I, Di Mario C, Moses J, et al. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results. Circulation 1997; 96:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/6\">",
"      Thomas WJ, Cowley MJ, Vetrovec GW, et al. Effectiveness of rotational atherectomy in narrowed left internal mammary artery grafts to the left anterior descending coronary artery. Am J Cardiol 2000; 86:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/7\">",
"      Kishi K, Hiasa Y, Ogata T, et al. Comparison of results of rotational atherectomy for diffuse coronary artery disease in diabetics versus nondiabetics. Am J Cardiol 2001; 87:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/8\">",
"      Dauerman HL, Baim DS, Cutlip DE, et al. Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998; 82:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/9\">",
"      Sharma SK, Duvvuri S, Dangas G, et al. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. J Am Coll Cardiol 1998; 32:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/10\">",
"      Radke PW, Klues HG, Haager PK, et al. Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study. J Am Coll Cardiol 1999; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/11\">",
"      vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation 2002; 105:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/12\">",
"      Kini A, Reich D, Marmur JD, et al. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. Am Heart J 2001; 142:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/13\">",
"      Koch KC, vom Dahl J, Kleinhans E, et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999; 33:998.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     King, SB, Smith, SC, Hirshfeld, JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for PCI. Circulation 2008; 117:e1. Available at: file://circ.ahajournals.org (accessed January 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/16\">",
"      Mart&iacute; V, Mart&iacute;n V, Garc&iacute;a J, et al. Significance of angiographic coronary dissection after cutting balloon angioplasty. Am J Cardiol 1998; 81:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/17\">",
"      Adamian M, Colombo A, Briguori C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol 2001; 38:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/18\">",
"      Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004; 43:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/19\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/20\">",
"      Litvack F, Eigler N, Margolis J, et al. Percutaneous excimer laser coronary angioplasty: results in the first consecutive 3,000 patients. The ELCA Investigators. J Am Coll Cardiol 1994; 23:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/21\">",
"      K&ouml;ster R, Hamm CW, Seabra-Gomes R, et al. Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. J Am Coll Cardiol 1999; 34:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/22\">",
"      Mehran R, Mintz GS, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation 1997; 96:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/23\">",
"      Mehran R, Dangas G, Mintz GS, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation 2000; 101:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/24\">",
"      K&ouml;ster R, K&auml;hler J, Terres W, et al. Six-month clinical and angiographic outcome after successful excimer laser angioplasty for in-stent restenosis. J Am Coll Cardiol 2000; 36:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41142/abstract/25\">",
"      Hamburger JN, Foley DP, de Feyter PJ, et al. Six-month outcome after excimer laser coronary angioplasty for diffuse in-stent restenosis in native coronary arteries. Am J Cardiol 2000; 86:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1567 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-A3347AB727-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41142=[""].join("\n");
var outline_f40_11_41142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROTATIONAL ATHERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Calcified and complex lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Use prior to stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Internal mammary artery graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Saphenous vein graft lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use in diabetic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      In-stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjunctive therapy with abciximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rotational atherectomy summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIRECTIONAL CORONARY ATHERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CUTTING BALLOON ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EXCIMER LASER ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy for in-stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EXTRACTION THROMBECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8495455\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27108?source=related_link\">",
"      Coronary complications of atheroablative devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41143="ABCs of melanoma PI";
var content_f40_11_41143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Is it a mole or melanoma?",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Another thing to watch for in a mole is whether it is changing, or \"evolving.\" So remember:",
"    <br>",
"     A is for asymmetry",
"     <br>",
"      B is for border",
"      <br>",
"       C is for color",
"       <br>",
"        D is for diameter",
"        <br>",
"         E is for evolving",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Reproduced from: National Cancer Institute (",
"          <a href=\"file://www.cancer.gov\">",
"           file://www.cancer.gov",
"          </a>",
"          ).",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41143=[""].join("\n");
var outline_f40_11_41143=null;
var title_f40_11_41144="Oral lichen planus: Pathogenesis, clinical features, and diagnosis";
var content_f40_11_41144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Ginat W Mirowski, DMD, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Bethanee J Schlosser, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41144/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/11/41144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H190861120\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus (LP) is a chronic inflammatory disorder that affects the skin and mucous membranes. Oral LP is a mucosal subtype of LP that most commonly occurs in middle-aged adults. Oral LP may occur alone or in conjunction with other forms of LP (",
"    <a class=\"graphic graphic_picture graphicRef63590 graphicRef86813 graphicRef85620 \" href=\"mobipreview.htm?30/26/31146\">",
"     picture 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link&amp;anchor=H6#H6\">",
"     \"Lichen planus\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical findings of oral LP range from reticular white plaques to mucosal erythema, erosions, ulceration, and hyperkeratotic plaques (",
"    <a class=\"graphic graphic_picture graphicRef76338 graphicRef62826 graphicRef54143 \" href=\"mobipreview.htm?3/55/3961\">",
"     picture 2A-C",
"    </a>",
"    ). Although reticular lesions are often asymptomatic, pain frequently accompanies the other manifestations of oral LP.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of oral LP will be reviewed here. Discussion of the management of oral LP and reviews of other forms of LP are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26361?source=see_link\">",
"     \"Oral lichen planus: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link\">",
"     \"Lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36090?source=see_link&amp;anchor=H176463815#H176463815\">",
"     \"Overview of nail disorders\", section on 'Lichen planus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3848?source=see_link\">",
"     \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861127\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological data on oral LP vary. Population-based studies performed in Asia, Europe, North America, and the Middle East have found disease prevalence rates between less than 1 percent and 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral LP most commonly occurs in middle-aged adults. Large retrospective studies from Europe and the United States indicate that the average age of patients presenting with oral LP is around 50 to 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Oral LP is rare in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to cutaneous LP, which is more likely to occur in men than women, women may be more likely to develop oral LP than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/1-3,10-13\">",
"     1-3,10-13",
"    </a>",
"    ]. In a retrospective study of 723 patients with oral LP seen in an outpatient dermatology office in the United States, 75 percent of the patients were women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2\">",
"     2",
"    </a>",
"    ]. Moreover, a retrospective study of 808 patients referred to an oral medicine department in Italy found that 60 percent of the patients were women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861134\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenic mechanisms that lead to oral LP are not fully understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1669583\">",
"    <span class=\"h2\">",
"     Inciting factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common theory on the pathogenesis of oral LP is that an immune reaction against an exogenous or endogenous antigen triggers the onset of an aberrant immune response to an intrinsic skin antigen and the onset of the disease. Exposures to infections, trauma, drugs, and contact allergens as well as autoimmune disorders have been proposed as potential contributing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/14\">",
"     14",
"    </a>",
"    ]. However, a causative role for any of these factors in oral LP is unconfirmed.",
"   </p>",
"   <p>",
"    In particular, the relevance of hepatitis C virus in the pathogenesis of LP is uncertain. An increased prevalence of hepatitis C virus infection among patients with LP has been detected in some geographic locations, such as southern Europe and Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/15\">",
"     15",
"    </a>",
"    ]. Some Italian studies have identified the HLA-DR6 allele as a potential risk factor for hepatitis C virus-associated oral LP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The relationship between LP and the hepatitis C virus is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link&amp;anchor=H4#H4\">",
"     \"Lichen planus\", section on 'Hepatitis C virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although associations between oral LP and thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/18\">",
"     18",
"    </a>",
"    ] and oral LP and dyslipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/19\">",
"     19",
"    </a>",
"    ] have been reported, definitive links between oral LP and these disorders are not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21977696\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral LP is considered to be a T-cell mediated chronic inflammatory tissue reaction that results in a cytotoxic reaction against epithelial basal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/14\">",
"     14",
"    </a>",
"    ]. The inflammatory infiltrate in oral LP is primarily composed of CD8+ T cells. A potential pathway for CD8+ T cell-mediated cytotoxicity in oral LP is described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD8+ T cells are activated by antigens presented on MHC 1 molecules on keratinocytes or by encounters with activated CD4+ helper T cells or cytokines produced by activated CD4+ helper T cells",
"     </li>",
"     <li>",
"      Activated CD8+ T cells induce keratinocyte apoptosis through mechanisms such as secretion of tumor necrosis factor (TNF)-alpha, secretion of granzyme B, or Fas-Fas ligand interactions",
"     </li>",
"     <li>",
"      Activated CD8+ T cells produce chemokines that attract additional inflammatory cells, thereby promoting continued inflammation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that have been proposed as contributors to oral LP include the upregulation of matrix metalloproteinases that disrupt the epithelial basement membrane zone and allow entry of immune cells into the epidermis, the release of proinflammatory mediators and proteases by mast cells, and perturbations in the innate immune response that may involve toll-like receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/14,20-22\">",
"     14,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21977703\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors that influence immune function may contribute to oral LP. An Italian study found a significant increase in a genetic polymorphism of the first intron of the interferon (IFN)-gamma promoter in patients with oral LP compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/23\">",
"     23",
"    </a>",
"    ]. A separate study performed in China found an association between a polymorphism in the TNF-alpha gene and risk for oral LP in a subset of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861141\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral LP may be divided into three clinical subtypes:",
"    <strong>",
"     reticular",
"    </strong>",
"    ,",
"    <strong>",
"     erythematous (atrophic)",
"    </strong>",
"    , and",
"    <strong>",
"     erosive",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2,25,26\">",
"     2,25,26",
"    </a>",
"    ]. More than one subtype of oral LP may be present in an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106406489\">",
"    <span class=\"h2\">",
"     Clinical subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticular oral LP is the most common manifestation. It often occurs in conjunction with erythematous or erosive disease. As an example, in a retrospective study of 723 patients with oral LP, erythematous and erosive manifestations were the predominant findings in 37 and 40 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2\">",
"     2",
"    </a>",
"    ]. In almost all cases, reticular disease also was present. The remaining 23 percent of patients had isolated reticular oral LP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Reticular oral LP",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Reticular oral LP is usually asymptomatic and characterized by the presence of white lines, papules, or plaques in a reticulated or lacy pattern on the oral mucosa (",
"      <a class=\"graphic graphic_picture graphicRef76338 graphicRef86887 graphicRef86889 \" href=\"mobipreview.htm?15/3/15418\">",
"       picture 2A, 2D-E",
"      </a>",
"      ). The term &ldquo;Wickham&rsquo;s striae&rdquo; is often used to describe this clinical presentation. Large, painful, hyperkeratotic plaques on the tongue are a less common manifestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2,25\">",
"       2,25",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Erythematous oral LP",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Erythematous oral LP typically occurs in conjunction with reticular lesions. Areas of mucosal atrophy, appearing as red patches among the white papules, patches, or plaques of reticular LP are usually present (",
"      <a class=\"graphic graphic_picture graphicRef54143 \" href=\"mobipreview.htm?27/10/27808\">",
"       picture 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Erosive oral LP",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Erosive oral LP is characterized by erosions or frank ulcers (",
"      <a class=\"graphic graphic_picture graphicRef62826 \" href=\"mobipreview.htm?37/20/38209\">",
"       picture 2B",
"      </a>",
"      ). Rarely, bullae that easily rupture occur. Lesions consistent with erosive oral LP are usually accompanied by both reticular and erythematous lesions (",
"      <a class=\"graphic graphic_picture graphicRef86888 \" href=\"mobipreview.htm?12/34/12835\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manifestations of oral LP are usually seen bilaterally and in a symmetric distribution. The most common site of involvement is the posterior buccal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/27\">",
"     27",
"    </a>",
"    ]. Other common sites are the gingiva, labial mucosa, tongue, and vermillion of the lower lip (",
"    <a class=\"graphic graphic_picture graphicRef86886 \" href=\"mobipreview.htm?6/11/6325\">",
"     picture 4",
"    </a>",
"    ). Infrequently, lesions develop on the palate, floor of the mouth, or upper lip.",
"   </p>",
"   <p>",
"    Desquamative gingivitis, a term which refers to the development of widespread erosions on the gingiva, may be seen in a variety of inflammatory mucosal disorders, including oral LP (",
"    <a class=\"graphic graphic_picture graphicRef86885 \" href=\"mobipreview.htm?23/28/24003\">",
"     picture 5",
"    </a>",
"    ). Around 10 percent of patients with oral LP have isolated gingival disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike reticular LP, which is often asymptomatic, the erythematous and erosive forms of oral LP are typically accompanied by symptoms. Patients may note pain, a burning sensation, swelling, or irritation, and may experience mucosal bleeding in response to mild trauma, such as toothbrushing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/26\">",
"     26",
"    </a>",
"    ]. Additional clinical findings that may be noted in oral LP include the Koebner phenomenon (the development of new lesions at sites of trauma) and mucoceles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual postinflammatory hyperpigmentation, manifesting as brown to black pigment on the oral mucosa, has been reported in association with oral LP, and may be most likely to occur in dark-skinned individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/31\">",
"     31",
"    </a>",
"    ]. Lesions of erosive LP may resolve with scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21977006\">",
"    <span class=\"h2\">",
"     Extraoral findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral LP may occur in isolation or in conjunction with other clinical manifestations of LP, including cutaneous LP, genital LP, nail LP, and lichen planopilaris (scalp LP). As an example, a retrospective study of 584 patients with oral LP found cutaneous LP, nail LP, and lichen planopilaris were present in 16, 2, and 1 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/32\">",
"     32",
"    </a>",
"    ]. Genital involvement was detected in 77 of 399 examined women (19 percent) and 8 of 174 men (5 percent). Brief descriptions of these extraoral forms of LP are provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cutaneous LP",
"      </strong>",
"      &ndash; Cutaneous LP is typically characterized by the appearance of polygonal, violaceous, pruritic papules on the trunk or extremities (",
"      <a class=\"graphic graphic_picture graphicRef63590 graphicRef76383 graphicRef54396 \" href=\"mobipreview.htm?12/63/13306\">",
"       picture 1A, 1D-E",
"      </a>",
"      ). Oral LP is common among individuals with cutaneous LP. It is estimated that more than 50 percent of individuals with cutaneous LP also have oral lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/25,33\">",
"       25,33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link&amp;anchor=H6#H6\">",
"       \"Lichen planus\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lichen planopilaris",
"      </strong>",
"      &ndash; Lichen planopilaris is a form of scarring alopecia characterized by atrophic plaques and subtle follicular hyperkeratosis (",
"      <a class=\"graphic graphic_picture graphicRef86813 \" href=\"mobipreview.htm?9/30/9703\">",
"       picture 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Nail LP",
"      </strong>",
"      &ndash; Nail involvement in LP may manifest as grooves or ridges in the nail plate (trachyonychia) (",
"      <a class=\"graphic graphic_picture graphicRef85620 \" href=\"mobipreview.htm?30/12/30915\">",
"       picture 1C",
"      </a>",
"      ) or with onycholysis and pterygium formation (",
"      <a class=\"graphic graphic_picture graphicRef86822 \" href=\"mobipreview.htm?38/24/39297\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36090?source=see_link&amp;anchor=H176463815#H176463815\">",
"       \"Overview of nail disorders\", section on 'Lichen planus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Genital (vulvar, vaginal, or penile) LP",
"      </strong>",
"      &ndash; The clinical findings of vulvar LP include erythema, erosions, white reticulated plaques, and scarring (",
"      <a class=\"graphic graphic_picture graphicRef86858 \" href=\"mobipreview.htm?26/49/27412\">",
"       picture 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Lesions may be asymptomatic, pruritic, or painful, and may be accompanied by dysuria or dyspareunia. Annular lesions are a common manifestation of penile LP (",
"      <a class=\"graphic graphic_picture graphicRef76913 graphicRef53806 \" href=\"mobipreview.htm?7/41/7833\">",
"       picture 8A-B",
"      </a>",
"      ). The terms &ldquo;vulvovaginal-gingival syndrome&rdquo; and &ldquo;peno-gingival syndrome&rdquo; describe patients who have both genital LP and gingiva-predominant oral LP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=see_link&amp;anchor=H2#H2\">",
"       \"Vulvar lichen planus\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, LP involves the ocular, nasal, laryngeal, esophageal, anal, or ear mucosa. Involvement of these areas may lead to scarring that results in functional limitations. Patients with ocular involvement usually present with symptoms of erythema and irritation of the palpebral and bulbar conjunctiva, which can eventually progress to a cicatrizing conjunctivitis and blindness (",
"    <a class=\"graphic graphic_picture graphicRef86875 \" href=\"mobipreview.htm?6/63/7155\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. LP of the nasal mucosa usually presents with erythema and erosions; reticular findings are rare. Laryngeal involvement may initially present with hoarseness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/41\">",
"     41",
"    </a>",
"    ], and esophageal involvement may be associated with dysphagia or odynophagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/42\">",
"     42",
"    </a>",
"    ]. Anal erythema, erosions, or papules may be noted in patients with anal LP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/38\">",
"     38",
"    </a>",
"    ]. Involvement of the external auditory canals with erosive LP leading to conductive deafness has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861148\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of oral LP is confirmed through review of the patient history, physical examination, and histological findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21507480\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation should include a patient history that assesses the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of LP involving other body sites or other skin disorders that may present with similar findings (eg, autoimmune blistering diseases)",
"     </li>",
"     <li>",
"      Presence of associated symptoms (eg, pain, burning)",
"     </li>",
"     <li>",
"      Presence of symptoms suggestive of other sites of mucosal involvement (eg, dysphagia, hoarseness, stridor, ocular irritation, dysuria, dyspareunia, hematuria)",
"     </li>",
"     <li>",
"      Medication list to evaluate for the possibility of an oral lichenoid drug eruption (may occur weeks to months after drug initiation) (",
"      <a class=\"graphic graphic_table graphicRef83762 \" href=\"mobipreview.htm?1/20/1357\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      History of dental restorations, use of dental appliances, or oral exposure to substances that may cause oral lichenoid contact eruptions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A full examination that includes the evaluation of the mucosal and cutaneous surfaces, including the vulva, vagina, penis, scalp, and nails should be performed. Thorough examination may lead to the detection of extraoral manifestations of LP that provide additional support for the diagnosis or the identification of clinical findings that suggest another diagnosis. In addition, the presence of dental restoration materials (eg, amalgam fillings) that could contribute to a lichenoid contact reaction should be noted. (See",
"    <a class=\"local\" href=\"#H21977006\">",
"     'Extraoral findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H190861169\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861155\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue biopsies of oral LP help to confirm the diagnosis and are particularly of value for erythematous and erosive LP, which share features with multiple other mucosal disorders, including oral malignancy. Thus, we biopsy all patients who exhibit features of these subtypes. Biopsies to confirm oral LP are less essential in patients who present with classic reticular LP, particularly in patients in whom a diagnosis of LP has already been confirmed through biopsy of an extraoral manifestation of this disorder.",
"   </p>",
"   <p>",
"    A 4 mm punch biopsy of lesional tissue that extends into the submucosa usually provides a sufficient specimen for histological examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. If reticular LP is present in conjunction with erythematous or erosive manifestations, biopsy of the reticular area is preferred for diagnosis of oral LP. Biopsies taken from reticular areas have intact epithelium and may be less likely to yield nonspecific findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2\">",
"     2",
"    </a>",
"    ]. However, erythematous or erosive lesions should be biopsied when considering possible malignancy transformation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26361?source=see_link&amp;anchor=H172227122#H172227122\">",
"     \"Oral lichen planus: Management and prognosis\", section on 'Risk of oral squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histological findings of oral LP can offer strong support for the diagnosis, but are not pathognomonic. Clinical correlation is required. Common histological findings of oral LP include (",
"    <a class=\"graphic graphic_picture graphicRef86856 graphicRef86857 \" href=\"mobipreview.htm?29/54/30570\">",
"     picture 10A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parakeratosis and slight acanthosis of the epithelium",
"     </li>",
"     <li>",
"      Saw-toothed rete ridges",
"     </li>",
"     <li>",
"      Liquefaction degeneration of the basal layer with apoptotic keratinocytes (referred to as Civatte, colloid, hyaline, or cytoid bodies)",
"     </li>",
"     <li>",
"      An amorphous band of eosinophilic material at the basement membrane",
"     </li>",
"     <li>",
"      A lichenoid (band-like) mixed lymphohistiocytic infiltrate in the submucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases where the clinical and histological findings are inconclusive, direct immunofluorescence (DIF) microscopy of perilesional mucosa is used to exclude autoimmune vesiculobullous disorders (eg, pemphigus, pemphigoid, linear IgA bullous dermatosis). In oral LP, DIF usually demonstrates globular deposits of IgM in the submucosa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H53290533#H53290533\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861162\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests may be ordered based upon clinical suspicion for other conditions. The possibility of",
"    <em>",
"     Candida",
"    </em>",
"    infection or herpes simplex virus reactivation should be considered in patients who experience acute exacerbations of disease severity despite previously effective treatment. Erosions or ulcers that fail to resolve or exhibit atypical features should be biopsied to rule out malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26361?source=see_link&amp;anchor=H172227122#H172227122\">",
"     \"Oral lichen planus: Management and prognosis\", section on 'Risk of oral squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for hepatitis C virus infection in patients with LP is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=see_link&amp;anchor=H5#H5\">",
"     \"Lichen planus\", section on 'Screening for HCV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190861169\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation to determine the underlying cause of red or white oral lesions should be performed in all patients who present with such lesions. The differential diagnosis of oral LP is particularly broad, given the various clinical manifestations of the condition (see",
"    <a class=\"local\" href=\"#H106406489\">",
"     'Clinical subtypes'",
"    </a>",
"    above). Careful review of the patient history, examination findings, and biopsy results is useful for distinguishing oral LP from other disorders.",
"   </p>",
"   <p>",
"    Select disorders in the differential diagnosis of oral LP are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Leukoedema",
"      </strong>",
"      &ndash; Leukoedema is a common, benign finding in the oral cavity that presents as white-gray, somewhat translucent plaques on the mucosa (",
"      <a class=\"graphic graphic_picture graphicRef86890 \" href=\"mobipreview.htm?1/32/1538\">",
"       picture 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. The buccal mucosa is the most common site for involvement. Symptoms are absent, and no treatment is necessary.",
"     </li>",
"     <li>",
"      <strong>",
"       Oropharyngeal candidiasis",
"      </strong>",
"      &ndash; Oropharyngeal candidiasis (also known as thrush) is a common infection that has a predilection for infants, elderly adults with dentures, immunosuppressed individuals, and individuals utilizing intraoral corticosteroid therapy. Patients present with white plaques or erythematous patches on the buccal mucosa, palate, tongue, or oropharynx that may be mistaken for reticular LP (",
"      <a class=\"graphic graphic_picture graphicRef61040 graphicRef75887 graphicRef79519 \" href=\"mobipreview.htm?38/51/39735\">",
"       picture 12A-C",
"      </a>",
"      ). The diagnosis can be made quickly by performing a potassium hydroxide (KOH) preparation. Oropharyngeal candidiasis may coexist with oral LP as a result of topical corticosteroid therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Oropharyngeal candidiasis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"       \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Leukoplakia",
"      </strong>",
"      &ndash; Leukoplakia is a manifestation of squamous epithelial hyperplasia that may be a precursor to oral squamous cell carcinoma. White patches or plaques develop on the oral mucosa (",
"      <a class=\"graphic graphic_picture graphicRef81049 graphicRef72711 \" href=\"mobipreview.htm?0/26/423\">",
"       picture 13A-B",
"      </a>",
"      ). A biopsy of leukoplakia is indicated to rule out malignancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=see_link&amp;anchor=H4#H4\">",
"       \"Oral lesions\", section on 'Leukoplakia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oral squamous cell carcinoma",
"      </strong>",
"      &ndash; Oral squamous cell carcinoma can present as erythematous or white patches, ulcers, or exophytic masses (",
"      <a class=\"graphic graphic_picture graphicRef81810 \" href=\"mobipreview.htm?43/47/44784\">",
"       picture 14",
"      </a>",
"      ). A biopsy is useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=see_link&amp;anchor=H3#H3\">",
"       \"Oral lesions\", section on 'Squamous cell carcinoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26361?source=see_link&amp;anchor=H172227122#H172227122\">",
"       \"Oral lichen planus: Management and prognosis\", section on 'Risk of oral squamous cell carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oral lichenoid drug reaction",
"      </strong>",
"      &ndash; Lichenoid drug eruptions may be caused by a variety of systemic medications (",
"      <a class=\"graphic graphic_table graphicRef83762 \" href=\"mobipreview.htm?1/20/1357\">",
"       table 1",
"      </a>",
"      ) and share clinical features with oral LP. Histological findings of a deep mixed infiltrate with lymphocytes, plasma cells, and neutrophils (with or without eosinophils) and perivascular inflammation favor this diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3848?source=see_link\">",
"       \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oral lichenoid contact reaction (allergic contact mucositis)",
"      </strong>",
"      &ndash; Oral lichenoid contact reactions may be caused by a variety of substances. Mercury-containing amalgam used for dental restoration is the most common cause [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/25\">",
"       25",
"      </a>",
"      ]. The clinical and histological features of oral lichenoid contact reactions are similar to oral LP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/48\">",
"       48",
"      </a>",
"      ]. Patch testing and recognition of the proximity of an offending substance to the eruption can aid with diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Autoimmune blistering diseases",
"      </strong>",
"      &ndash; Mucous membrane pemphigoid and other autoimmune blistering diseases may present with oral erosions and desquamative gingivitis similar to that seen in erosive LP. Biopsies for routine histological examination and direct immunofluorescence are useful for distinguishing these disorders from oral LP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H784094#H784094\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=see_link&amp;anchor=H28759745#H28759745\">",
"       \"Linear IgA bullous dermatosis\", section on 'Mucosal involvement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=see_link&amp;anchor=H4624835#H4624835\">",
"       \"Epidermolysis bullosa acquisita\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Graft-versus-host disease",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Lacy, reticulated plaques or erosions that resemble oral LP may occur in chronic graft-versus-host disease (GVHD) (",
"      <a class=\"graphic graphic_picture graphicRef73344 graphicRef61588 graphicRef82463 \" href=\"mobipreview.htm?6/21/6490\">",
"       picture 15A-C",
"      </a>",
"      ). The histological findings of these disorders are also similar. The patient history is useful for differentiating chronic GVHD from oral LP. Oral involvement in acute GVHD is less well-characterized than chronic GVHD, but has been associated with erythematous, erosive, ulcerative, or lichenoid oral lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41144/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42073?source=see_link&amp;anchor=H18902850#H18902850\">",
"       \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Chronic cutaneous GVHD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42073?source=see_link&amp;anchor=H18902803#H18902803\">",
"       \"Cutaneous manifestations of graft-versus-host disease (GVHD)\", section on 'Acute cutaneous GVHD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of other disorders that may present with oral white plaques include syphilis (",
"    <a class=\"graphic graphic_picture graphicRef66087 \" href=\"mobipreview.htm?42/15/43251\">",
"     picture 16",
"    </a>",
"    ), oral hairy leukoplakia (",
"    <a class=\"graphic graphic_picture graphicRef86947 \" href=\"mobipreview.htm?25/20/25925\">",
"     picture 17",
"    </a>",
"    ), oral condyloma (",
"    <a class=\"graphic graphic_picture graphicRef86949 \" href=\"mobipreview.htm?38/53/39762\">",
"     picture 18",
"    </a>",
"    ), and white sponge nevus (",
"    <a class=\"graphic graphic_picture graphicRef86948 \" href=\"mobipreview.htm?6/13/6356\">",
"     picture 19",
"    </a>",
"    ). Additional disorders in the differential diagnosis of erythematous and erosive oral LP include aphthous stomatitis (",
"    <a class=\"graphic graphic_picture graphicRef63475 \" href=\"mobipreview.htm?13/25/13713\">",
"     picture 20",
"    </a>",
"    ), erythroplakia (",
"    <a class=\"graphic graphic_picture graphicRef87511 \" href=\"mobipreview.htm?38/42/39588\">",
"     picture 21",
"    </a>",
"    ), and syphilis (",
"    <a class=\"graphic graphic_picture graphicRef82771 \" href=\"mobipreview.htm?23/49/24338\">",
"     picture 22",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/28/6594?source=see_link\">",
"       \"Patient information: Lichen planus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172228193\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral lichen planus (LP) is a subtype of LP that most commonly occurs in middle-aged adults. Women are more likely to develop oral LP than men. Individuals of all ethnic backgrounds may be affected. (See",
"      <a class=\"local\" href=\"#H190861127\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of oral LP is not fully understood, but appears to involve an immune-mediated cytotoxic reaction against epithelial cells. Activated CD8+ T-cells may play a key role. The inciting factors for oral LP are unknown. (See",
"      <a class=\"local\" href=\"#H190861134\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings of oral LP can be divided into reticular, erythematous (atrophic), and erosive subtypes. Many patients with reticular LP also have erythematous or erosive lesions. The buccal mucosa is the most common site for oral LP. (See",
"      <a class=\"local\" href=\"#H190861141\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral LP may occur as the only manifestation of LP or in conjunction with other features of the disorder. Oral LP is common among individuals with cutaneous LP, and many women with oral LP have associated genital (vaginal or vulvar) involvement. (See",
"      <a class=\"local\" href=\"#H21977006\">",
"       'Extraoral findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with oral LP may have involvement of other mucosal surfaces, which can result in functional limitations if untreated. Thus, the patient evaluation should include inquiries regarding the presence of ocular, nasal, laryngeal, esophageal, or anogenital symptoms. (See",
"      <a class=\"local\" href=\"#H21977006\">",
"       'Extraoral findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H190861148\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of oral LP can usually be made based upon the review of clinical and histological findings. Direct immunofluorescence is helpful for ruling out autoimmune blistering diseases that involve the mucosa in challenging cases. (See",
"      <a class=\"local\" href=\"#H190861148\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/1\">",
"      McCartan BE, Healy CM. The reported prevalence of oral lichen planus: a review and critique. J Oral Pathol Med 2008; 37:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/2\">",
"      Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/3\">",
"      Carbone M, Arduino PG, Carrozzo M, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis 2009; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/4\">",
"      Bermejo-Fenoll A, S&aacute;nchez-Siles M, L&oacute;pez-Jornet P, et al. A retrospective clinicopathological study of 550 patients with oral lichen planus in south-eastern Spain. J Oral Pathol Med 2010; 39:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/5\">",
"      Walton KE, Bowers EV, Drolet BA, Holland KE. Childhood lichen planus: demographics of a U.S. population. Pediatr Dermatol 2010; 27:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/6\">",
"      Kanwar AJ, De D. Lichen planus in children. Indian J Dermatol Venereol Leprol 2010; 76:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/7\">",
"      GunaShekhar M, Sudhakar R, Shahul M, et al. Oral lichen planus in childhood: A rare case report. Dermatol Online J 2010; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/8\">",
"      Anuradha Ch, Reddy GS, Nandan SR, et al. Oral mucosal lichen planus in nine-year-old child. N Y State Dent J 2011; 77:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/9\">",
"      Patel S, Yeoman CM, Murphy R. Oral lichen planus in childhood: a report of three cases. Int J Paediatr Dent 2005; 15:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/10\">",
"      Hellgren L. The prevalence of lichen ruber planus in different geographical areas in Sweden. Acta Derm Venereol 1970; 50:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/11\">",
"      Nagao T, Ikeda N, Fukano H, et al. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. J Oral Pathol Med 2005; 34:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/12\">",
"      Xue JL, Fan MW, Wang SZ, et al. A clinical study of 674 patients with oral lichen planus in China. J Oral Pathol Med 2005; 34:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/13\">",
"      Thorn JJ, Holmstrup P, Rindum J, Pindborg JJ. Course of various clinical forms of oral lichen planus. A prospective follow-up study of 611 patients. J Oral Pathol 1988; 17:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/14\">",
"      Roopashree MR, Gondhalekar RV, Shashikanth MC, et al. Pathogenesis of oral lichen planus--a review. J Oral Pathol Med 2010; 39:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/15\">",
"      Shengyuan L, Songpo Y, Wen W, et al. Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis. Arch Dermatol 2009; 145:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/16\">",
"      Carrozzo M, Brancatello F, Dametto E, et al. Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6? J Oral Pathol Med 2005; 34:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/17\">",
"      Carrozzo M, Francia Di Celle P, Gandolfo S, et al. Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral lichen planus. Br J Dermatol 2001; 144:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/18\">",
"      Siponen M, Huuskonen L, L&auml;&auml;r&auml; E, Salo T. Association of oral lichen planus with thyroid disease in a Finnish population: a retrospective case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/19\">",
"      Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol 2009; 161:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/20\">",
"      Siponen M, Kauppila JH, Soini Y, Salo T. TLR4 and TLR9 are induced in oral lichen planus. J Oral Pathol Med 2012; 41:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/21\">",
"      El Tawdy A, Rashed L. Downregulation of TLR-7 receptor in hepatic and non-hepatic patients with lichen planus. Int J Dermatol 2012; 51:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/22\">",
"      Janardhanam SB, Prakasam S, Swaminathan VT, et al. Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus. Arch Oral Biol 2012; 57:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/23\">",
"      Carrozzo M, Uboldi de Capei M, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004; 122:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/24\">",
"      Jin X, Wang J, Zhu L, et al. Association between -308 G/A polymorphism in TNF-&alpha; gene and lichen planus: a meta-analysis. J Dermatol Sci 2012; 68:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/25\">",
"      Schlosser BJ. Lichen planus and lichenoid reactions of the oral mucosa. Dermatol Ther 2010; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/26\">",
"      Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 2003; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/27\">",
"      Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005; 11:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/28\">",
"      Scully C, el-Kom M. Lichen planus: review and update on pathogenesis. J Oral Pathol 1985; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/29\">",
"      Bermejo A, Aguirre JM, L&oacute;pez P, Saez MR. Superficial mucocele: report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/30\">",
"      Eveson JW. Superficial mucoceles: pitfall in clinical and microscopic diagnosis. Oral Surg Oral Med Oral Pathol 1988; 66:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/31\">",
"      Mergoni G, Ergun S, Vescovi P, et al. Oral postinflammatory pigmentation: an analysis of 7 cases. Med Oral Patol Oral Cir Bucal 2011; 16:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/32\">",
"      Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/33\">",
"      Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol 2010; 28:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/34\">",
"      Goettmann S, Zaraa I, Moulonguet I. Nail lichen planus: epidemiological, clinical, pathological, therapeutic and prognosis study of 67 cases. J Eur Acad Dermatol Venereol 2012; 26:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/35\">",
"      McPherson T, Cooper S. Vulval lichen sclerosus and lichen planus. Dermatol Ther 2010; 23:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/36\">",
"      Mirowski GW, Goddard A. Treatment of vulvovaginal lichen planus. Dermatol Clin 2010; 28:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/37\">",
"      Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. Int J Dermatol 1989; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/38\">",
"      Rogers RS 3rd, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin 2003; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/39\">",
"      Brewer JD, Ekdawi NS, Torgerson RR, et al. Lichen planus and cicatricial conjunctivitis: disease course and response to therapy of 11 patients. J Eur Acad Dermatol Venereol 2011; 25:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/40\">",
"      Webber NK, Setterfield JF, Lewis FM, Neill SM. Lacrimal canalicular duct scarring in patients with lichen planus. Arch Dermatol 2012; 148:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/41\">",
"      Rennie CE, Dwivedi RC, Khan AS, et al. Lichen planus of the larynx. J Laryngol Otol 2011; 125:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/42\">",
"      Fox LP, Lightdale CJ, Grossman ME. Lichen planus of the esophagus: what dermatologists need to know. J Am Acad Dermatol 2011; 65:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/43\">",
"      Martin L, Moriniere S, Machet MC, et al. Bilateral conductive deafness related to erosive lichen planus. J Laryngol Otol 1998; 112:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/44\">",
"      Agha R, Mirowski GW. The art and science of oral examination. Dermatol Ther 2010; 23:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/45\">",
"      Eisen D. The oral mucosal punch biopsy. A report of 140 cases. Arch Dermatol 1992; 128:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/46\">",
"      Duncan SC, Su WP. Leukoedema of the oral mucosa. Possibly an acquired white sponge nevus. Arch Dermatol 1980; 116:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/47\">",
"      Martin JL. Leukoedema: a review of the literature. J Natl Med Assoc 1992; 84:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/48\">",
"      Thornhill MH, Sankar V, Xu XJ, et al. The role of histopathological characteristics in distinguishing amalgam-associated oral lichenoid reactions and oral lichen planus. J Oral Pathol Med 2006; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41144/abstract/49\">",
"      Vargas-D&iacute;ez E, Garc&iacute;a-D&iacute;ez A, Mar&iacute;n A, Fern&aacute;ndez-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol 2005; 23:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15285 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41144=[""].join("\n");
var outline_f40_11_41144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172228193\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861120\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861127\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861134\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1669583\">",
"      Inciting factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21977696\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21977703\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861141\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106406489\">",
"      Clinical subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21977006\">",
"      Extraoral findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861148\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21507480\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190861155\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190861162\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190861169\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172228193\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15285|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/29/18898\" title=\"picture 1A\">",
"      Lichen planus flexures dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9703\" title=\"picture 1B\">",
"      Lichen planopilaris with erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/12/30915\" title=\"picture 1C\">",
"      Lichen planus trachyonychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/42/29346\" title=\"picture 1D\">",
"      Lichen planus wrists fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/6/23652\" title=\"picture 1E\">",
"      Hypertrophic lichen planus lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/30/20961\" title=\"picture 2A\">",
"      Lichen planus - oral Wickham striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/20/38209\" title=\"picture 2B\">",
"      Oral lichen planus - erosive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/10/27808\" title=\"picture 2C\">",
"      Oral lichen planus - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/53/11093\" title=\"picture 2D\">",
"      Oral lichen planus - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/10/11427\" title=\"picture 2E\">",
"      Oral lichen planus - reticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/34/12835\" title=\"picture 3\">",
"      Oral lichen planus - multiple features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/11/6325\" title=\"picture 4\">",
"      Oral lichen planus - lower lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/28/24003\" title=\"picture 5\">",
"      Oral lichen planus - desquamative gingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/24/39297\" title=\"picture 6\">",
"      Nail lichen planus pterygium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/49/27412\" title=\"picture 7\">",
"      Vulvovaginal lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/48/13059\" title=\"picture 8A\">",
"      Annular lichen planus - penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/9/21653\" title=\"picture 8B\">",
"      Annular lichen planus on penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/63/7155\" title=\"picture 9\">",
"      Ocular lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/12/16580\" title=\"picture 10A\">",
"      Oral lichen planus histopathology - Lichenoid infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/23/20857\" title=\"picture 10B\">",
"      Oral lichen planus histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/32/1538\" title=\"picture 11\">",
"      Leukoedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/30/28128\" title=\"picture 12A\">",
"      Oral candidiasis - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/12/5312\" title=\"picture 12B\">",
"      Oropharyngeal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/32/7680\" title=\"picture 12C\">",
"      Candida denture stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/2/18464\" title=\"picture 13A\">",
"      Leukoplakia - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/39/2675\" title=\"picture 13B\">",
"      Leukoplakia - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/47/44784\" title=\"picture 14\">",
"      Squamous cell carcinoma - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/16/11520\" title=\"picture 15A\">",
"      Chronic GVHD buccal mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/37/28245\" title=\"picture 15B\">",
"      Chronic GVHD tongue erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/33/25106\" title=\"picture 15C\">",
"      Chronic GVHD tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/15/43251\" title=\"picture 16\">",
"      Mucous patch secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/20/25925\" title=\"picture 17\">",
"      Oral hairy leukoplakia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/53/39762\" title=\"picture 18\">",
"      Oral condyloma acuminatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/13/6356\" title=\"picture 19\">",
"      White sponge nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/25/13713\" title=\"picture 20\">",
"      Aphthous ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/42/39588\" title=\"picture 21\">",
"      Erythroplakia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/49/24338\" title=\"picture 22\">",
"      Primary syphilis oral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15285|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/20/1357\" title=\"table 1\">",
"      Drugs causing lichenoid eruptions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42073?source=related_link\">",
"      Cutaneous manifestations of graft-versus-host disease (GVHD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3848?source=related_link\">",
"      Lichenoid drug eruption (drug-induced lichen planus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26361?source=related_link\">",
"      Oral lichen planus: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36090?source=related_link\">",
"      Overview of nail disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/28/6594?source=related_link\">",
"      Patient information: Lichen planus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41145="Late DAD micrograph";
var content_f40_11_41145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late diffuse alveolar damage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 185px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows changes typical of the proliferative or late stage of diffuse alveolar damage. Although hyaline membranes are still identifiable, the histologic picture is now dominated by thickening and reorganization of interstitial structures due mainly to marked proliferation of mesenchymal spindle cells, including both fibroblasts and myofibroblasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumoctes (red arrow) and smaller numbers of cuboidal type II pneumocytes (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41145=[""].join("\n");
var outline_f40_11_41145=null;
var title_f40_11_41146="Systemic treatment of metastatic soft tissue sarcoma";
var content_f40_11_41146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment of metastatic soft tissue sarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Suzanne George, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     George D Demetri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/11/41146/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/11/41146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas (STS) are a heterogeneous group of rare tumors that arise from mesenchymal cells at all body sites. The malignant precursor cell(s) can differentiate along one or several lineages, such as muscle, adipose, fibrous, cartilage, nerve, or vascular tissue. These tumors arise most often in the limbs (particularly the lower extremity), followed in order of frequency by the abdominal",
"    <span class=\"nowrap\">",
"     cavity/retroperitoneum,",
"    </span>",
"    <span class=\"nowrap\">",
"     trunk/thoracic",
"    </span>",
"    region and the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227086#H12227086\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While local complications from primary or recurrent sarcomas can cause significant morbidity and occasional mortality, the most life-threatening aspect of sarcomas is their propensity for hematogenous dissemination. The pattern of tumor spread varies according to tumor type:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most soft tissue sarcomas of the extremity, chest wall, head or neck, the primary metastatic site is the lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. However, there are exceptions. Extrapulmonary metastases to the retroperitoneum, spine, and paraspinous soft tissues predominate with",
"      <span class=\"nowrap\">",
"       myxoid/round",
"      </span>",
"      cell liposarcomas, although lung metastases develop eventually in almost all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227107#H12227107\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Pattern of spread'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227114#H12227114\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Pattern of recurrence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With retroperitoneal and visceral sarcomas, the primary site of failure is local. Less commonly, these tumors spread hematogenously to the liver [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spread to locoregional lymph nodes is rare except with clear cell and epithelioid sarcomas, angiosarcomas, and with rhabdomyosarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification of soft tissue sarcomas, insight into their molecular pathogenesis, and the definition of optimal treatment strategies have evolved considerably over the past 10 to 25 years. There are more than 50 histologic subtypes of STS, many of which are associated with distinctive clinical profiles, response to individual therapies, and prognosis. While in the past these tumors were all \"lumped\" together and treated similarly, consensus is emerging that the selection of treatment should be histology-driven, particularly in the setting of advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients who develop metastatic",
"    <strong>",
"    </strong>",
"    STS are incurable; however, therapeutic nihilism is unwarranted for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median survival after development of distant metastases is 11 to 15 months, and 20 to 25 percent of patients are still alive at two to three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. The prognostic factors for more prolonged survival differ from those predicting response to chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/6\">",
"       6",
"      </a>",
"      ], suggesting that survival is more dependent upon disease biology rather than solely on treatment-associated considerations.",
"     </li>",
"     <li>",
"      Potentially curative options should be sought in appropriate patients so that the opportunity for cure is not overlooked. In selected patients, resection of pulmonary metastases is feasible, with reported five-year survival 25 to 40 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with metastatic unresectable disease, judicious use of systemic therapy provides meaningful symptom palliation, prevents rapid disease progression, and may, in some cases, prolong survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic chemotherapy for metastatic non-GIST STS will be reviewed here. The primary management of localized STS of the extremity, trunk, or retroperitoneum, adjuvant and neoadjuvant treatments, surgical management of metastatic STS, and systemic therapy for specific types of STS including gastrointestinal stromal tumors (GIST), rhabdomyosarcoma, desmoids, dermatofibrosarcoma protuberans, and Kaposi's sarcoma are discussed elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unresectable metastatic STS, judicious use of systemic therapy provides meaningful palliation and may prolong survival. The selection of systemic therapy must be individualized and based upon several factors, including the histology and biologic behavior of the disease, as well as the health status and preferences of the patient.",
"   </p>",
"   <p>",
"    The following sections will consider treatment for non-GIST common adult type STS. Tyrosine kinase inhibitor therapy for GISTs, as well as treatment for rhabdomyosarcoma (which is far more common in children), Ewing sarcoma and osteosarcoma, and other bone sarcomas are covered elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unresectable metastatic STS is, with rare exception, a fatal disease eventually. If all detectable disease can be eliminated by the use of chemotherapy alone or combined with surgery and radiation therapy (RT), a few patients may enter a prolonged remission. There are sizable numbers of clinical anecdotes that describe patients who have no evidence of disease more than 10 to 20 years following multimodality management of metastatic STS. However, for the majority of patients with metastatic STS, chemotherapy is administered with palliative intent to decrease tumor bulk, diminish symptoms, and improve quality of life.",
"   </p>",
"   <p>",
"    In contrast to many other solid tumor types, many patients with metastatic STS will remain asymptomatic for long periods, sometimes for years. For these patients, chemotherapy may be considered to reduce tumor size or slow the inexorable pace of the disease. While it is hoped that survival may also be favorably impacted, there are no controlled clinical trials to indicate the magnitude of any such benefit, if it exists. Furthermore, any potential benefits from systemic therapy might be offset by treatment-related toxicities, particularly when combination chemotherapy is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Natural history of metastatic soft tissue sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of metastatic soft tissue sarcoma can be illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report in an era before GIST was recognized as a distinct clinical entity, outcomes from over 2000 patients treated with anthracycline-based chemotherapy for advanced STS were examined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/6\">",
"       6",
"      </a>",
"      ]. Median survival was approximately one year for the entire cohort, regardless of the specific regimen used. The likelihood of a chemotherapy response was greater in younger patients with high-grade non-leiomyosarcoma histology and no hepatic metastases, while longer median survival was predicted by a good performance status, low-grade histology, the absence of liver metastases, and a longer recurrence-free interval.",
"     </li>",
"     <li>",
"      In a more modern series, 488 patients were treated with first-line chemotherapy for advanced",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic STS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/9\">",
"       9",
"      </a>",
"      ]. In multivariate analysis, age &lt;40 years, liposarcoma or synovial sarcoma histology, lack of bone metastases, and combination rather than single agent therapy were associated with a better outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles can be applied to therapeutic decision making. As an example, for some patients with asymptomatic low-grade unresectable disease (eg, low grade intraabdominal leiomyosarcoma), it might be reasonable to follow the patient without active chemotherapy. Conversely, for patients with a high-grade chemotherapy-sensitive tumor such as synovial sarcoma or liposarcoma, early use of combination chemotherapy may be preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histologic subtype and response to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have been severely hampered by the admixture of a variety of histologic subtypes in the analysis of outcome, making it difficult to assess the clinical activity of any given treatment. The interpretation of clinical trial results will be heavily weighted by the distribution of histologic subtypes. This, in turn, complicates the assessment of chemotherapy efficacy, making it impossible to determine whether high or low response rates are due to the specific treatment or to the specific population under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is increasingly recognized that different histologic subtypes of STS exhibit variable patterns of chemosensitivity. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial sarcomas and",
"      <span class=\"nowrap\">",
"       myxoid/round",
"      </span>",
"      cell liposarcomas are among the more chemotherapy-sensitive subtypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In particular,",
"      <span class=\"nowrap\">",
"       myxoid/round",
"      </span>",
"      cell liposarcomas tend to be sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -based chemotherapy, and synovial sarcoma appears especially sensitive to alkylating agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      . In contrast, other subtypes, such as GIST and some non-uterine leiomyosarcomas appear to have lower response rates to conventional anthracycline and ifosfamide-based chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/6,14\">",
"       6,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leiomyosarcomas of uterine origin, endometrial stromal sarcomas, myxofibrosarcoma, dedifferentiated liposarcoma, and malignant peripheral nerve sheath tumors (MPNSTs) exhibit considerable individual variability in their patterns of chemosensitivity. However, responses have been observed with anthracyclines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus ifosfamide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/15\">",
"       15",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based regimens. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Gemcitabine-based combinations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Myxoid/round",
"      </span>",
"      cell liposarcomas appear to be particularly sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      , a unique marine-derived agent that kills cells by poisoning the DNA nucleotide excision repair machinery. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Trabectedin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In contrast to virtually every other histology, angiosarcomas, particularly those arising on the scalp, are sensitive to taxanes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link&amp;anchor=H15#H15\">",
"       \"Head and neck sarcomas\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Taxanes and angiosarcoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For many tumor types that do not respond to conventional cytotoxic chemotherapy, research on molecular pathogenesis has provided crucial clues as to novel therapeutic strategies. For example, clinical trials conclusively demonstrate the impressive efficacy of the tyrosine kinase inhibitors (TKIs)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (Gleevec) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (Sutent) for patients with advanced GIST, a disease for which there was previously no highly effective treatment options for metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Similarly, benefit has been shown for sunitinib in patients with solitary fibrous",
"    <span class=\"nowrap\">",
"     tumor/hemangiopericytoma,",
"    </span>",
"    alveolar soft parts sarcoma, and clear cell sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/16-19\">",
"     16-19",
"    </a>",
"    ], for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in patients with neoplasms with perivascular epithelioid cell differentiation (PEComas, including recurrent",
"    <span class=\"nowrap\">",
"     angiomyolipoma/lymphangioleiomyomatosis)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/20-24\">",
"     20-24",
"    </a>",
"    ], and for imatinib in patients with pigmented villonodular",
"    <span class=\"nowrap\">",
"     synovitis/tenosynovial",
"    </span>",
"    giant cell tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There are also data supporting activity of imatinib in patients with metastatic dermatofibroma protuberans, and for imatinib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in patients with desmoid tumors. However, there are better data for single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    , single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    and combination",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"      methotrexate",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"      vinblastine",
"     </a>",
"    </span>",
"    in patients with desmoid tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link&amp;anchor=H7#H7\">",
"     \"Desmoid tumors: Systemic therapy\", section on 'Non-cytotoxic approaches'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=see_link&amp;anchor=H15#H15\">",
"     \"Pulmonary lymphangioleiomyomatosis\", section on 'Sirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of TKIs for GISTs has prompted exploration of other molecularly targeted therapies for STS that are not sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . As an example, emerging data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , an orally active multitargeted TKI that inhibits Raf kinase and blocks the intracellular portion of the VEGF receptor may be an active agent for certain angiosarcomas, as well as perhaps some subtypes of leiomyosarcoma, although additional study is needed to confirm the initial reports. Furthermore,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    seems to be an active agent for alveolar soft parts sarcoma. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Molecularly targeted therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These data have led to the emergence of the concept of histology-driven treatment rather than a \"one size fits all\" approach to therapy in patients with metastatic STS. The most recent consensus-based recommendations for treatment of metastatic soft tissue sarcoma from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    provide specific chemotherapy regimen recommendations for angiosarcoma, solitary fibrous",
"    <span class=\"nowrap\">",
"     tumor/hemangiopericytoma,",
"    </span>",
"    alveolar soft part sarcoma,",
"    <span class=\"nowrap\">",
"     PEComa/",
"    </span>",
"    recurrent",
"    <span class=\"nowrap\">",
"     angiomyolipoma/lymphangioleiomyomatosis,",
"    </span>",
"    and chordoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link&amp;anchor=H14#H14\">",
"     \"Chordoma and chondrosarcoma of the skull base\", section on 'Advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     End points to define clinical benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific endpoints that best reflect clinical benefit from systemic therapy in metastatic soft tissue sarcoma are unclear. Objective response rates, as judged by a decrease in the size of measurable lesions, are increasingly considered to be poor surrogates for clinical benefit in this disease. This may be at least partly due to the fact that many sarcomas contain densely hyalinized desmoplastic stromal tissues. Even in cases where systemic treatment successfully induces massive tumor cell kill in vivo, such hyalinized tissue remains unchanged, leading to a falsely negative assessment of the true response to treatment and an underestimation of antitumor efficacy. The \"disconnect\" between objective tumor response and clinical benefit is particularly evident in studies of drugs like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    and molecularly targeted therapies.",
"   </p>",
"   <p>",
"    Increasing attention is being paid to other important indicators of clinical outcomes, such as progression-free survival, the progression-free rate at a specific time point (often 12 weeks), percentage survival at a given time point, overall survival, and disease stabilization. A therapeutic agent that is associated with a low objective antitumor response may slow tumor progression and prolong survival. Stabilization of disease is increasingly viewed as a realistic end point for metastatic STS. However, the generation of clinical data to support these alternative end points requires rigorous attention to the consistency of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only single agents that are consistently associated with response rates of more than 20 percent in metastatic STS are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . Even for these agents, the range of objective activity between various small (and even larger) trials is impressive, demonstrating the variability in disease sensitivity (noted above) and the fact that any given STS patient population could serve as an important confounding variable for interpretation of drug efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of STS to systemic chemotherapy was first demonstrated with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    in the early 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/27\">",
"     27",
"    </a>",
"    ], and subsequent studies suggested a dose-response relationship. The threshold dose for optimal activity appears be &ge;60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle, usually administered once every three weeks, with lower doses associated with inferior antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/28\">",
"     28",
"    </a>",
"    ]. It is difficult to demonstrate a clinically meaningful dose-response relationship with single agent doxorubicin at doses beyond 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle.",
"   </p>",
"   <p>",
"    Even in modern multi-institutional series using 70 to 80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle, there is significant variability in reported response rates which range from 10 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]. The vast majority are partial rather than complete responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    is associated with reversible myelosuppression, mucositis, alopecia, nausea and vomiting, and both acute and chronic cardiotoxicity. This drug has a relatively narrow therapeutic index; even small variations of dose beyond 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    can drastically worsen patient tolerance, and even 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is considered by many patients to be significantly more toxic than 60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Infusional rather than bolus administration reduces the likelihood of cardiotoxicity. Other methods to diminish cardiotoxicity include the concomitant use of the cardioprotectant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    or the use of liposome-encapsulated doxorubicin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pegylated liposomal doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liposomal encapsulation appears to improve the side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , thereby increasing the therapeutic index. The most widely used preparation (Doxil&reg; in the United States and Caelyx&reg; in Europe) is a large liposome with polyethylene glycol (PEG) anchored within the lipid bilayer, which acts as a hydrophilic coating to prolong the circulating half-life of the liposome by preventing degradation within the reticuloendothelial system. The toxicity profile is somewhat different from nonencapsulated doxorubicin, mainly consisting of an acute hypersensitivity-like reaction in approximately 8 percent of patients, palmar-plantar erythrodysesthesia (\"hand-foot syndrome\"), and esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liposomal anthracyclines are active in STS, but it is unclear if they are as efficacious as unencapsulated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/29,36-38\">",
"     29,36-38",
"    </a>",
"    ]. In a randomized phase II trial, Doxil (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every four weeks) was compared to unencapsulated doxorubicin (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/29\">",
"     29",
"    </a>",
"    ]. Although Doxil was well tolerated and appeared to have similar efficacy compared to doxorubicin, the response rates in both arms were low, 10 and 9 percent, respectively. Of note, there was a high proportion of GIST in this study population, emphasizing the importance of disease subtype as a confounding factor in studies of chemotherapy efficacy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Histologic subtype and response to chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On the basis of this trial, rigorous clinical trial rules would have discarded both unencapsulated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and Doxil as putatively \"inactive\" agents in STS, with response rates &lt;20 percent. This would be a major error, since doxorubicin has important clinical activity, proven over the past 30 years, in patients with advanced STS. These data underscore the poor correlation between objective response rate and clinical benefit, and the need for caution in interpreting any clinical trial of a new drug as \"negative\" based upon objective tumor shrinkage. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'End points to define clinical benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Others report response rates of 50 percent or higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    , which are durable in many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/39\">",
"     39",
"    </a>",
"    ]. Doxil is a widely used agent for metastatic STS, particularly outside of the US and in patients aged 65 or older.",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    also has activity in angiosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/38,40,41\">",
"     38,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Epirubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    is less cardiotoxic on a mg to mg basis. At least two trials have directly compared epirubicin with single agent doxorubicin for STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An EORTC trial randomly assigned 334 patients with untreated metastatic STS to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      on one of two different schedules (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for three days or 150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/42\">",
"       42",
"      </a>",
"      ]. Neither epirubicin schedule was associated with better response rate or survival, and cardiovascular and hematologic toxicity were worse than with doxorubicin.",
"     </li>",
"     <li>",
"      In the second trial, 210 patients received either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (both dosed at 75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      once every three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/33\">",
"       33",
"      </a>",
"      ]. There was a slight trend toward a lower response rate with epirubicin (18 versus 25 percent), but response duration and median survival were similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    has similar antitumor activity as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Response rates are 7 and 41 percent (average 25 percent) among patients who previously failed a doxorubicin-based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/10,43-50\">",
"     10,43-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    is challenging to administer, especially considering the variety of published doses and schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/10,50\">",
"     10,50",
"    </a>",
"    ]. Ifosfamide can be delivered over one or several consecutive days; infusional schedules may be less toxic than bolus administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/45-48,50,51\">",
"     45-48,50,51",
"    </a>",
"    ]. Ifosfamide-related toxicities differ from those associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ; they include hemorrhagic cystitis, renal tubular acidosis, salt-wasting nephropathy, and central nervous system toxicity.",
"   </p>",
"   <p>",
"    Concurrent administration of the uroprotectant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    decreases hemorrhagic cystitis. Mesna binds to the active metabolite acrolein, decreasing the incidence of hemorrhagic cystitis (a different metabolite, chloracetaldehyde, is thought to be responsible for the nephrotoxicity). Mesna is usually administered immediately following and four and eight hours after each",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14806?source=see_link\">",
"     \"Ifosfamide nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link\">",
"     \"Cystitis in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A dose-response relationship has been shown for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    in metastatic STS; the threshold is approximately 6",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/10,47\">",
"     10,47",
"    </a>",
"    ]. Additional responses can be demonstrated with &ge;10",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least one trial directly compared single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) versus two different doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over four hours daily for three days or 9",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 72 hours by continuous infusion) in patients with advanced STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/54\">",
"     54",
"    </a>",
"    ]. Antitumor efficacy was similar, and toxicity was worse in both ifosfamide groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Taxanes and angiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes as single agents are relatively inactive except in angiosarcoma.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    is particularly useful for advanced angiosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/38,55-60\">",
"     38,55-60",
"    </a>",
"    ]. Weekly therapy was more active than every three week therapy in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    is also an active agent for angiosarcoma, and whether the antitumor efficacy of taxanes surpasses that of doxorubicin for this histology is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gemcitabine and other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conventional cytotoxic drugs with modest antitumor activity include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/62,63\">",
"     62,63",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/64\">",
"     64",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (particularly for leiomyosarcoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/65-68\">",
"     65-68",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/69\">",
"     69",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/70\">",
"     70",
"    </a>",
"    ]. All are associated with response rates less than 20 percent, but additional patients have stable disease, some for prolonged periods.",
"   </p>",
"   <p>",
"    There are conflicting data as to the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/71-78\">",
"     71-78",
"    </a>",
"    ]. In one report, gemcitabine administered by fixed dose rate infusion",
"    <span class=\"nowrap\">",
"     (mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /min)",
"    </span>",
"    was associated with a partial response in 4 of 10 patients with non-GI leiomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/72\">",
"     72",
"    </a>",
"    ]. Other studies suggest little activity for gemcitabine monotherapy, both in previously treated and untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. In most of these studies, the drug was administered over 30 minutes, but a preliminary report of a French trial reported an objective response rate of only 5 percent in 20 patients treated with fixed dose rate gemcitabine, but two-thirds had prolonged periods of stable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (administered by dose rate infusion) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    appear to be active in leiomyosarcoma of uterine and gastrointestinal origin, as well as other histologies. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Gemcitabine-based combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a single agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    has low activity overall, but response rates are modest in non-uterine leiomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different combination regimens have been studied in patients with metastatic disease; most include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and an alkylating agent.",
"   </p>",
"   <p>",
"    The most commonly used multiagent regimens are (",
"    <a class=\"graphic graphic_table graphicRef80881 \" href=\"mobipreview.htm?21/21/21854\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      (AIM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/30,31,80,81\">",
"       30,31,80,81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      MAID (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/85,86\">",
"       85,86",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/88\">",
"       88",
"      </a>",
"      ], or alternating with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <span class=\"nowrap\">",
"       (VAC/IE)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CyVADIC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/30,90\">",
"       30,90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      (AD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/28,64,82,91\">",
"       28,64,82,91",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/53/9046?source=see_link\">",
"       liposomal daunorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/92\">",
"       92",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These moderately intensive combination chemotherapy regimens are associated with overall response rates in the range of 16 to 46 percent, with complete responses in 5 to 10 percent. Approximately one-third of the complete responders (ie, 1 to 3 percent of patients with advanced STS overall) are long-term disease-free survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/83,90,93-95\">",
"     83,90,93-95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Doxorubicin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized studies and a pooled analysis have compared these combinations to each other and to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/28,30,31,34,64,82,90,91,96,97\">",
"     28,30,31,34,64,82,90,91,96,97",
"    </a>",
"    ]. The following general conclusions can be drawn from these series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most randomized prospective trials, combination regimens delivered at conventional doses, such as MAID, AIM (",
"      <a class=\"graphic graphic_table graphicRef56240 \" href=\"mobipreview.htm?37/54/38766\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67985 \" href=\"mobipreview.htm?40/20/41294\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81370 \" href=\"mobipreview.htm?2/42/2735\">",
"       table 4",
"      </a>",
"      ), AD, and are associated with higher response rates (27 to 46 percent) than single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , but fewer than 10 percent are complete. Responses are generally short lived (median about eight months).",
"     </li>",
"     <li>",
"      In randomized trials, no combination regimen has been associated with significantly longer survival than single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , despite modestly higher response rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/97,98\">",
"       97,98",
"      </a>",
"      ] and in a preliminary report of EORTC 62012, median progression-free survival rates (7.4 versus 4.6 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/97\">",
"       97",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Combination versus single agent therapy'",
"      </a>",
"      below.).",
"     </li>",
"     <li>",
"      Although combination regimens are clearly associated with greater toxicity than single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , strategies such as infusional administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      or doxorubicin over three to four days through a central venous catheter can markedly diminish the dacarbazine-associated emesis and doxorubicin cardiotoxicity. Hematopoietic growth factor support can significantly reduce the myelosuppression associated with MAID [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/99\">",
"       99",
"      </a>",
"      ] and AIM, although in the preliminary report of EORTC 62012, in which all patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"       pegfilgrastim",
"      </a>",
"      as primary prophylaxis, the rate of febrile neutropenia was still quite high (46 versus 14 percent with single agent doxorubicin alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/97\">",
"       97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"       \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      results in neither a response nor a survival advantage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/34,90,100\">",
"       34,90,100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      in combination regimens is similarly active and similarly toxic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Combination versus single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above considerations, the benefit of multiagent compared to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based chemotherapy for advanced STS remains controversial. The goal of therapy is an important consideration. Many of the clinical trials noted above have enrolled patients with \"advanced\" STS, which may include bulky unresectable but not metastatic disease. The utility and rationale for aggressive preoperative combination chemotherapy is quite different in this setting than for patients with multifocal metastatic disease. Neoadjuvant chemotherapy may shrink a large tumor and permit subsequent locoregional therapy, even possibly with curative intent. In contrast, in the setting of multifocal metastatic disease, the goal of therapy is palliation. It is difficult to differentiate between these clinical settings in many reported clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although combination chemotherapy is an accepted practice standard in the US, it is not necessarily the first-line approach to metastatic STS in other parts of the world.",
"   </p>",
"   <p>",
"    The above data, specifically the lack of evidence supporting an overall survival benefit from combination chemotherapy compared to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    for patients with metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/98\">",
"     98",
"    </a>",
"    ], suggest that single agent doxorubicin is the benchmark against which newer single and multiagent regimens must be tested. Sequential administration of active single chemotherapy agents may maximize the duration of disease control and minimize treatment-associated toxicities.",
"   </p>",
"   <p>",
"    However, initial combination chemotherapy may be of benefit for selected patients, for example, a patient with acute pain or an immediate life-threatening problem (eg, impending bronchial obstruction); in this case, the greater likelihood of an objective response justifies the increased toxicity of combination therapy in an otherwise healthy patient.",
"   </p>",
"   <p>",
"    Another argument in favor of multiagent chemotherapy in patients with good performance status is that complete responses are more likely than with single agent regimens. Although few patients with unresectable metastatic STS will be long-term survivors, the achievement of a complete response to chemotherapy is the most powerful predictor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Gemcitabine-based combinations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1458931\">",
"    <span class=\"h4\">",
"     Gemcitabine plus docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58713 \" href=\"mobipreview.htm?25/6/25710\">",
"     table 5",
"    </a>",
"    ) was initially reported in a study of 34 patients with leiomyosarcoma of uterine (n = 29) or gastrointestinal (GI, n = 5) origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/85\">",
"     85",
"    </a>",
"    ]; 53 percent had an objective response, including two of the five with GI leiomyosarcoma. More recent data suggest that this regimen may have a broader range of activity, although response rates appear to be lower in histologies other than leiomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/86,102\">",
"     86,102",
"    </a>",
"    ]. As an example, a retrospective review of 133 patients treated with gemcitabine and docetaxel included 76 leiomyosarcomas and 57 other histologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/102\">",
"     102",
"    </a>",
"    ]. Only 17 percent were chemotherapy-naive. The overall response rate was 18 percent (24 versus 10 percent for leiomyosarcoma and other histologies, respectively). At 12 and 24 months, 51 and 15 percent of patients were still alive, respectively.",
"   </p>",
"   <p>",
"    Lower doses (particularly of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) may be needed for patients with prior radiation to fields encompassing large amounts of marrow.",
"   </p>",
"   <p>",
"    As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone is an active single agent in metastatic STS when administered as a fixed rate infusion. The superiority of",
"    <span class=\"nowrap\">",
"     gemcitabine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"      docetaxel",
"     </a>",
"    </span>",
"    over gemcitabine alone was addressed in a multicenter phase III trial comparing gemcitabine with and without docetaxel that used a novel Bayesian adaptive randomization strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/103\">",
"     103",
"    </a>",
"    ]. This allows for continuous outcomes monitoring, incrementally assigning more patients to the superior treatment arm, while accounting for possible treatment-subgroup interactions (eg, histology, prior radiation therapy [RT] versus none, performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/104\">",
"     104",
"    </a>",
"    ]).",
"    <br/>",
"    <br/>",
"    The treatment arms were gemcitabine alone (1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8 every 21 days; 900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in patients with prior pelvic RT) or gemcitabine (900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 8; 675",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if prior pelvic RT) plus docetaxel (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 8; 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    if prior pelvic RT), with courses repeated every 21 days. In both arms, gemcitabine was given via fixed dose rate infusion (10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /min).",
"    </span>",
"    All patients received growth factor support.",
"    <br/>",
"    <br/>",
"    Forty-nine patients were adaptively randomized to gemcitabine alone, 73 to gemcitabine plus docetaxel. The primary endpoint (tumor response, a complete or partial response or stable disease for at least 24 weeks) was met by 27 versus 32 percent of patients receiving gemcitabine alone and combined therapy, respectively. The objective response rate with combined therapy was higher (16 versus 8 percent), as was progression-free survival (PFS, 6.2 versus 3 months) and overall survival (17.9 versus 11.5 months), respectively. Patients with leiomyosarcoma and malignant fibrous",
"    <span class=\"nowrap\">",
"     histiocytoma/undifferentiated",
"    </span>",
"    pleomorphic STS appeared to derive the most benefit. However, these benefits came at the cost of greater toxicity (particularly edema and constitutional symptoms). Significantly more patients receiving combined therapy discontinued treatment due to toxicity.",
"   </p>",
"   <p>",
"    On the other hand, the benefit of combined therapy over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone, particularly for non-uterine leiomyosarcomas, was called into question by the results of a randomized phase II trial in which 90 patients with metastatic leiomyosarcoma of uterine (n = 46) or non-uterine (n = 44) origin were randomly assigned to gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, and 15 of each 28-day cycle), or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 8 of a 21-day cycle), with primary prophylaxis with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/105\">",
"     105",
"    </a>",
"    ]. Among patients with uterine leiomyosarcoma, response rate was only modestly higher with combined therapy (24 versus 19 percent), and median progression-free survival was not better (4.7 versus 5.5 months). Among those with non-uterine leiomyosarcomas, the response rate to combined therapy was low (5 versus 14 percent with gemcitabine alone), and median progression-free survival was only 3.8 months (versus 6.3 months for gemcitabine monotherapy). Patients receiving single agent gemcitabine experienced less toxicity.",
"   </p>",
"   <p>",
"    Although the authors concluded that both treatments were similarly efficacious, at least for uterine leiomyosarcomas, the trial was conducted as a parallel set of two phase II studies, and the study lacked power to determine which treatment was better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/106\">",
"     106",
"    </a>",
"    ]. An important finding was that a high proportion of patients in both arms (&gt;40 percent, highest in the non-uterine leiomyosarcoma group) had durable stable disease, and the six-month progression-free survival rate in all groups was &ge;47 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2793077\">",
"    <span class=\"h4\">",
"     Gemcitabine plus dacarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (DTIC) over DTIC alone was shown in a phase II trial in which 113 patients with previously treated STS were randomly assigned to DTIC (1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) or fixed-dose rate gemcitabine (1800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /min)",
"    </span>",
"    followed by DTIC (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    every two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/107\">",
"     107",
"    </a>",
"    ]. Combined therapy was associated with significantly higher median PFS (4.2 versus 2 months), overall survival (16.8 versus 8.2 months) and overall clinical benefit (objective response plus stable disease, 49 versus 25 percent). Severe toxicity was uncommon with combined treatment; grade 3 or 4 neutropenia occurred in over 30 percent of patients, but febrile neutropenia was rare. Grade 1 or 2 asthenia, emesis, and stomatitis were the most frequent nonhematologic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1458950\">",
"    <span class=\"h4\">",
"     Gemcitabine plus vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 8) plus fixed-dose rate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 90 minutes days 1 and 8) was shown in a single-institution trial of 40 patients with unresectable or metastatic STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/87\">",
"     87",
"    </a>",
"    ]. There was one complete and four partial responses, and five patients had stable disease for at least four months (clinical benefit rate 25 percent). Three of the five responders had leiomyosarcoma, two of uterine origin, one had a myxofibrosarcoma and one a small round blue cell tumor. One-half of all patients had grade 3 or 4 hematologic toxicity, fewer than 5 percent with febrile neutropenia. Whether these results are better than can be achieved with",
"    <span class=\"nowrap\">",
"     gemcitabine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"      docetaxel",
"     </a>",
"    </span>",
"    requires a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dose intensification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the demonstrated dose-response relationship with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , higher than standard dose chemotherapy has been studied in STS. Higher doses of doxorubicin and ifosfamide can be administered in combination regimens with the support of hematopoietic growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/80,96,108-113\">",
"     80,96,108-113",
"    </a>",
"    ] or autologous hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/114-118\">",
"     114-118",
"    </a>",
"    ]; however, there is no clear overall survival benefit for higher as compared to standard dosing regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Growth factor support",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with metastatic disease, dose intensive combination chemotherapy has been associated with objective response rates as high as 67 percent and a higher proportion of complete responses compared to conventional dose regimens. However, these benefits are achieved at the expense of greater multiorgan toxicity, which may compromise quality of life. Furthermore, survival is not improved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial included 314 patients with advanced STS who were randomly assigned to either a low standard dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) or to higher dose doxorubicin (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus ifosfamide (5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF), all repeated every three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/80\">",
"       80",
"      </a>",
"      ]. Higher dose therapy was associated with a significantly longer PFS (29 versus 19 weeks); however, there were no differences in response rates (21 versus 23 percent), or two-year survival (24 versus 26 percent).",
"      <br/>",
"      <br/>",
"      Advocates of dose intensification argue that patient selection may have played some role in this negative trial and that the results may not be applicable to other patient populations who might have a higher likelihood of response. The trial population had a high incidence of leiomyosarcoma with primary site unknown (so they could have been gastrointestinal stromal tumors [GISTs]) and liver metastases, which are associated with a poor prognosis. In addition, patients receiving dose-intensified therapy had a threefold higher rate of neutropenic infection compared to those receiving conventional doses, despite G-CSF support. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"       \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      However, treatment with intensified (versus conventionally-dosed) MAID, or sequential high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      (versus standard-dose doxorubicin alone) did not improve response rates or survival in two other phase III trials which specifically excluded GIST [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/96,113\">",
"       96,113",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stem cell support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of HDT with stem cell support for the usual adult types of STS is also unproven. A systematic review included data from three randomized trials (only one of which was a published phase III trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/80\">",
"     80",
"    </a>",
"    ]), 12 phase II studies, and five phase I dose escalation trials evaluating dose-intensive chemotherapy with either growth factor or autologous bone",
"    <span class=\"nowrap\">",
"     marrow/stem",
"    </span>",
"    cell support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/119\">",
"     119",
"    </a>",
"    ]. The authors concluded that despite the higher response rates, there was no evidence of a significant survival benefit of HDT over conventional dose therapy in patients with advanced adult types of STS. The same conclusion was reached in a later published phase III trial of high dose therapy as consolidation after standard-dose chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significantly greater toxicity associated with these procedures would have to be accompanied by a much higher level of antitumor activity to justify the risks of treatment. More selective trials in specifically defined subsets of patients with STS are needed.",
"   </p>",
"   <p>",
"    In summary, these approaches must be considered investigational for metastatic STS and performed only in the context of innovative exploratory new trials or appropriately controlled phase III clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEW TREATMENT STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limited efficacy of conventional cytotoxic chemotherapy, STS represents a fertile ground for the field of drug development. Clinical trials in a number of areas have shown promise in metastatic STS.",
"   </p>",
"   <p>",
"    Performing valid clinical trials in STS is challenging because the different histologic types can behave differently; as a result, clinical trials must be stratified by histologic subtype for adequate interpretation of results. In order to generate studies of sufficient size and power, large-scale collaborations are required on a national and international level. Such collaborations are already in place in the US and among the nations of Europe, in Scandinavia, Italy, and Canada. With these collaborations, it is hoped that further research will rapidly translate research findings into the novel therapeutics which are so desperately required by patients with sarcomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Trabectedin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The novel marine-derived alkaloid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    (also called ecteinascidin, ET-743) kills cells by poisoning the DNA nucleotide excision repair machinery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/121\">",
"     121",
"    </a>",
"    ]. Trabectedin is an active agent for advanced STS, although the objective response rate by conventional criteria is fairly low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/122-126\">",
"     122-126",
"    </a>",
"    ]. Response rates have been highest in the",
"    <span class=\"nowrap\">",
"     myxoid/round",
"    </span>",
"    cell liposarcoma and leiomyosarcoma subtypes.",
"   </p>",
"   <p>",
"    Experience with this agent has also underscored the relevance of stable disease as a beneficial endpoint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/122-125,127,128\">",
"     122-125,127,128",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'End points to define clinical benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Phase II studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours every 21 days) performed both in patients failing prior chemotherapy and in those with previously untreated disease have yielded the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three separate studies of patients with previously treated STS, the objective response rates were 4 to 8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/123-125\">",
"       123-125",
"      </a>",
"      ]. In the first two series, approximately one-fourth of patients who had progressed while receiving a prior chemotherapy regimen had arrest of disease progression (an objective response or stable disease) at six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/123,124\">",
"       123,124",
"      </a>",
"      ]. In the larger of the two, the progression arrest rates for synovial sarcomas and leiomyosarcomas (which are particularly refractory to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ) were even higher, 61 and 56 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/124\">",
"       124",
"      </a>",
"      ]. The number of patients achieving stable disease as the best response was not reported in the third study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher response rate was noted in a phase II study conducted in 36 previously untreated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/129\">",
"       129",
"      </a>",
"      ]. There were six objective responses, one complete (response rate 17 percent), and three others (total 24 percent) remained progression-free at six months. While this level of antitumor activity is similar to that reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , the median duration of response was 16.5 months, median overall survival was 15.8 months and 72 percent of enrolled patients were still alive at one year. Toxicity was manageable, with 33 percent grade 4 neutropenia (no febrile neutropenia), grade 3 or 4 transient elevations in transaminase levels in about one-third, emesis (14 percent grade 3) and fatigue (11 percent grade 3 or 4).",
"     </li>",
"     <li>",
"      A particularly high response rate was seen in 51 patients with",
"      <span class=\"nowrap\">",
"       myxoid/round",
"      </span>",
"      cell liposarcoma who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      ; 51 percent had either a complete or partial response, and 88 percent were progression-free at six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/130\">",
"       130",
"      </a>",
"      ]. In a later analysis of 32 of the patients, followed for an average of 25 months, the median progression-free survival duration was 28 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/131\">",
"       131",
"      </a>",
"      ]. Similar to the situation observed with gastrointestinal stromal tumors treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , tumor response was marked by early radiologic alterations (decrease tumor density on CT or decrease in MRI contrast enhancement) followed by delayed tumor shrinkage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/130\">",
"       130",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results seem better than those achievable with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and combination doxorubicin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -based chemotherapy (median survival 9 to 12 months), randomized trials are needed. Neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    also seems promising for",
"    <span class=\"nowrap\">",
"     myxoid/round",
"    </span>",
"    cell liposarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=see_link&amp;anchor=H15#H15\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of the drug over 24-hours every three weeks was significantly superior to weekly dosing over three hours in a randomized phase II trial conducted in patients with previously treated advanced liposarcoma or leiomyosarcoma (median time to tumor progression 3.7 versus 2.3 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/127\">",
"     127",
"    </a>",
"    ]. Although somewhat higher rates of neutropenia, transaminase elevation, fatigue, and emesis occurred with the 24 hour schedule, the regimen was reasonably well tolerated by most patients.",
"   </p>",
"   <p>",
"    A report of extensive skin and soft tissue damage following subcutaneous extravasation has led to the recognition of the vesicant properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    , and a general recommendation that it be administered through a central venous access device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     Trabectedin",
"    </a>",
"    is not yet commercially available in the US. Trabectedin was approved by the European Medicines Agency (EMA) in 2007 and is available in Europe and in some other countries. A phase III randomized trial comparing trabectedin to DTIC in patients with advanced leiomyosarcoma and liposarcomas is currently underway in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary work suggests that the sensitivity of myxoid liposarcomas to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    may be related to the unique presence of a fusion oncoprotein that results from chromosomal translocation in this disease, and the ability of trabectedin to interfere with the ability of some fusion proteins to bind to promoters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/135\">",
"     135",
"    </a>",
"    ]. These data suggest that trabectedin represents a unique form of molecularly targeted therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic research has led to a new understanding of the biology and pathophysiology of STS; these findings are beginning to be translated into novel therapeutic strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most dramatic example of translation of molecular understanding of STS to a novel therapy is with the use of the selective tyrosine kinase inhibitor (TKI)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (Gleevec&reg;) to treat gastrointestinal stromal tumors (GISTs). Unfortunately, this agent is not useful in non-GIST STS with the exception of dermatofibrosarcoma protuberans and desmoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The insights gained from the study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and other TKIs in GIST has led to the identification of other TKIs that appear active in non-GIST soft tissue sarcomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antiangiogenic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8828453\">",
"    <span class=\"h4\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is a multitargeted orally active small molecule inhibitor of several TKs including the vascular endothelial growth factor receptor (VEGFR). Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft-tissue sarcoma subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/138\">",
"     138",
"    </a>",
"    ]. Based upon those results, a worldwide randomized, double-blinded phase III study (the PALETTE trial) was designed by EORTC and other investigators to compare pazopanib (800 mg daily) versus placebo in 369 patients with a variety of histologic subtypes (leiomyosarcoma, fibrosarcoma, synovial sarcoma, MPNST, vascular soft tissue sarcomas, sarcoma NOS, but not adipocytic sarcomas or GIST) whose disease had progressed during or after first-line chemotherapy (including an anthracycline) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/139\">",
"     139",
"    </a>",
"    ]. The median PFS was significantly higher in the pazopanib group (4.6 versus 1.6 months), and benefit was consistent across all histologic subtypes. There was no significant difference in overall survival (12.5 versus 10.7 months, HR 0.86, 95% CI 0.67-1.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/140\">",
"     140",
"    </a>",
"    ]. The best overall response was partial response in 6 versus 0 percent of the pazopanib and placebo groups, respectively, and stable disease in 67 versus 38 percent.",
"   </p>",
"   <p>",
"    The most common grade 3 or 4 treatment-related toxicities were fatigue, hypertension, diarrhea, anorexia, and transient elevation in liver function tests. A drop in left ventricular ejection fraction occurred in 16 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    compared to three cases in the placebo group (6.5 versus 2.4 percent); only three cases were symptomatic. Venous thromboembolism was more common in the pazopanib group (5 versus 2 percent, all grades). In addition, pneumothorax occurred in eight patients in the pazopanib group (3 percent), possibly due to necrosis of pleural lesions. Treatment-related toxicity in patients treated with TKIs that target VEGF is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, in April 2012,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    was approved in the US for treatment of patients with advanced soft tissue sarcoma (but not for adipocytic or gastrointestinal stromal tumors) who have received prior chemotherapy. Given the risk for potentially fatal hepatotoxicity, close monitoring of liver function tests is recommended, particularly in the first nine weeks of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H217131874#H217131874\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Pazopanib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8828792\">",
"    <span class=\"h4\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody targeting VEGF. The combination of bevacizumab plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    was evaluated in 17 anthracycline-naive patients with metastatic STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/141\">",
"     141",
"    </a>",
"    ]. Although there were only two partial responses (lasting for 21 to 36 weeks, both in patients with uterine leiomyosarcoma), 11 had stable disease for 12 weeks or more. Of concern, six patients developed grade 2 cardiac toxicity at cumulative doxorubicin doses of 75 to 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Given",
"    that efficacy was not substantially different from that expected with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone and the worrisome cardiotoxicity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been largely abandoned except in highly vascular tumors such as angiosarcoma. However, the available data are quite limited. In a phase II trial of bevacizumab in 32 patients with metastatic or locally advanced angiosarcoma or epithelioid hemangioendothelioma, only four patients (two angiosarcoma and two epithelioid hemangioendothelioma) had a partial response (17 percent), while 50 percent had tumor stabilization with a mean time to tumor progression of 26 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8828676\">",
"    <span class=\"h4\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is another multitargeted TKI that has limited activity in metastatic non-GIST STS, as evidenced by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II trial of 120 patients with six different histologic types of STS who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      400 mg twice daily, there was one objective partial response among 37 leiomyosarcomas, one complete and four partial responses among 37 angiosarcomas (14 percent), and no objective responses in MPNST, malignant fibrous histiocytoma, synovial sarcoma, or other histotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/143\">",
"       143",
"      </a>",
"      ]. Treatment-related toxicity was not trivial despite the use of the FDA-approved dose and schedule. Over 60 percent of patients required dose reduction, the majority due to dermatotoxicity. There were three grade 5 toxicities (one GI hemorrhage, intestinal perforation, and one fatal tension pneumothorax in a patient with pulmonary metastases).",
"     </li>",
"     <li>",
"      More modest activity against angiosarcoma was seen in another phase II trial of 51 patients with advanced vascular sarcomas, high-grade liposarcoma, and leiomyosarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/144\">",
"       144",
"      </a>",
"      ]. Six of the eight patients with some form of &ldquo;vascular sarcoma&rdquo; had prolonged periods of stable disease in this nonrandomized trial, although no objective antitumor responses were observed. Median progression-free survival in this group of &ldquo;vascular sarcomas&rdquo; was 5 months compared to 2 to 3 months for the other sarcoma histologies. Despite the same dose, the toxicity profile was more favorable than seen in the prior study; 50 percent required at least one dose reduction, but there were no grade 5 toxicities. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    , another multitargeted oral TKI, is active against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory GIST. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    for other histologic types of non-GIST sarcomas is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/16,145\">",
"     16,145",
"    </a>",
"    ]. Sunitinib appears active against the rare and chemotherapy-refractory alveolar soft part sarcoma, and has anecdotal activity against solitary fibrous",
"    <span class=\"nowrap\">",
"     tumor/hemangiopericytoma",
"    </span>",
"    and clear cell sarcoma. In a case series, two of four patients with progressive metastatic alveolar soft part sarcoma had an objective partial response with sunitinib 37.5 mg daily (one sustained for 12 months), and one had stable disease for at least three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/146\">",
"     146",
"    </a>",
"    ]. Treatment was reasonably well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Differentiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a critical regulator of fat cell differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/147\">",
"     147",
"    </a>",
"    ]. Since the pathophysiology of liposarcoma can be viewed as inhibited terminal differentiation with aberrant proliferation of cells of adipocyte lineage, the induction of terminal adipocyte differentiation might be clinically beneficial.",
"   </p>",
"   <p>",
"    Thiazolidinedione drugs such as troglitazone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , which were originally developed to treat diabetes mellitus, bind to and activate PPAR gamma. Although these agents can induce differentiation and reduce cellular proliferation in certain liposarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/148\">",
"     148",
"    </a>",
"    ], clinical experience with rosiglitazone monotherapy was disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular differentiation therapy is also being explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Modifying resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membrane-anchored drug efflux pumps, such as the p-glycoprotein (encoded by the MDR1 gene), might be responsible for resistance to anthracyclines and other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/151-153\">",
"     151-153",
"    </a>",
"    ]. In one report, MDR expression was found in one-third of high grade soft tissue sarcomas, and a good or moderate chemotherapy response was noted in 10 versus 32 percent of MDR positive versus negative cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Agents that selectively block p-glycoprotein and other multidrug resistance proteins might restore chemosensitivity to otherwise resistant sarcoma cells. As an example, the combination of biricodar (VX-710), a small molecule efflux pump inhibitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    produced stable disease and occasional responses in chemoresistant soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/154\">",
"     154",
"    </a>",
"    ]. Confirmation in large studies is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bendamustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    is a bifunctional alkylating agent that is not cross resistant with other DNA-interacting drugs (eg, anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ). Modest efficacy was suggested in a phase II trial of 36 patients with chemorefractory metastatic STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/155\">",
"     155",
"    </a>",
"    ]. There were few grade 3 or worse toxicities, one partial response (3 percent) and 11 with stable disease (31 percent). Six of 15 patients with leiomyosarcoma had disease stabilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Brostallicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brostallicin is a synthetic minor groove DNA binding agent that works only in the presence of glutathione (GSH) and glutathione-S transferase (GST), which are both overexpressed in malignant but not normal cells. A phase II trial noted two partial responses and 17 with stable disease among 43 patients with metastatic non-GIST STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/11/41146/abstract/156\">",
"     156",
"    </a>",
"    ]. A randomized comparison of doxorubicin versus brostallicin is ongoing by the EORTC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas are a heterogeneous group of rare tumors arising from mesenchymal cells at all body sites. While in the past these tumors were all \"lumped\" together and treated similarly, consensus is emerging that the selection of treatment should be histology driven, particularly in the setting of advanced disease. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Histologic subtype and response to chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For the majority of patients, treatment is palliative and not curative. Surgical resection of metastatic disease can provide long-term relapse-free survival and perhaps cure in selected patients, the majority of whom have isolated pulmonary metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meaningful symptom palliation and even prolongation of survival may accompany even a partial or minor response to systemic therapy. The following represents our general approach to advanced unresectable non-GIST STS. Treatment of patients with advanced GIST is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with advanced unresectable STS are appropriate candidates for clinical trials to identify more active single agents, combinations, or novel approaches. If participation in clinical trials is not feasible, conventional systemic therapy is an appropriate option for selected patients.",
"     </li>",
"     <li>",
"      For asymptomatic patients with unresectable disease and low-grade histologies that are associated with only a minor response to chemotherapy, we suggest deferring therapy with close interval surveillance to determine the pace of disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Constant clinical vigilance is imperative to avoid potentially life-threatening or painful adverse consequences from occult tumor progression.",
"     </li>",
"     <li>",
"      For symptomatic patients, and those with chemotherapy-sensitive histologies (eg, synovial sarcoma, myxoid liposarcoma, leiomyosarcoma, high-grade pleomorphic unclassified sarcoma), histology, clinical judgment, and patient preference influence the selection of the appropriate regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Choice of initial therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For angiosarcomas, we suggest a weekly taxane or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      monotherapy as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Taxanes and angiosarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For alveolar soft parts sarcoma, solitary fibrous",
"      <span class=\"nowrap\">",
"       tumor/hemangiopericytoma,",
"      </span>",
"      and clear cell sarcoma, we suggest considering therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      if a clinical trial option does not exist, and the patient has demonstrated progressive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Antiangiogenic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have neoplasms with perivascular epithelioid cell differentiation (PEComa), including recurrent",
"      <span class=\"nowrap\">",
"       angiomyolipoma/lymphangioleiomyomatosis,",
"      </span>",
"      we suggest considering therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , if a clinical trial option does not exist, and the patient has demonstrated progressive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Histologic subtype and response to chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pigmented villonodular",
"      <span class=\"nowrap\">",
"       synovitis/tenosynovial",
"      </span>",
"      giant cell tumor, we suggest considering therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , if a clinical trial option does not exist, and the patient has demonstrated progressive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      For other histologies, the best regimen has not been established. Higher response rates are achieved by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      -containing combinations such as AIM but at the cost of more toxicity as compared to sequential single agents. A brief trial of two cycles of combination chemotherapy may permit the rapid distinction between patients with highly chemotherapy-sensitive disease and those for whom this approach will provide toxicity without benefit.",
"      <br/>",
"      <br/>",
"      For young, symptomatic patients with an excellent performance status, we suggest combination rather than sequential single agent therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer doxorubicin 20 to 25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      by bolus injection daily for three days plus ifosfamide 2000 to 2500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily by bolus injection for three days with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      and growth factor support (",
"      <a class=\"graphic graphic_table graphicRef67985 \" href=\"mobipreview.htm?40/20/41294\">",
"       table 3",
"      </a>",
"      ). For older patients with adequate performance status and minimal comorbidity, smaller daily doses (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of doxorubicin and 2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of ifosfamide) are reasonable. Other variations of this regimen are available (",
"      <a class=\"graphic graphic_table graphicRef56240 \" href=\"mobipreview.htm?37/54/38766\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81370 \" href=\"mobipreview.htm?2/42/2735\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7410?source=see_link\">",
"       \"Treatment protocols for soft tissue and bone sarcoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For asymptomatic patients, single agent therapy with doxorubicin or ifosfamide is a reasonable option. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Doxorubicin-based regimens'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Whether initial therapy with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based regimen is preferable to an",
"      <span class=\"nowrap\">",
"       anthracycline/ifosfamide",
"      </span>",
"      combination for patients with leiomyosarcoma or undifferentiated sarcoma is uncertain. At some institutions, an anthracycline or an anthracycline plus ifosfamide remains the recommended first line treatment for these patients. Others disagree, choosing gemcitabine-based therapy (eg, gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , (",
"      <a class=\"graphic graphic_table graphicRef58713 \" href=\"mobipreview.htm?25/6/25710\">",
"       table 5",
"      </a>",
"      )) for first-line therapy of LMS, particularly uterine LMS. For other histologies (eg, synovial sarcoma), the response rate to gemcitabine-based therapy is close to zero. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Gemcitabine-based combinations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7410?source=see_link\">",
"       \"Treatment protocols for soft tissue and bone sarcoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Despite lower response rates, we suggest sequential single agent therapy (eg, doxorubicin followed by ifosfamide or other agents in succession) rather than combination therapy for patients with low-volume or slow-growing disease, or a poor performance status (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Doxorubicin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-dose chemotherapy is not a standard approach to treatment of advanced STS of the usual adult types, and we recommend that this approach not be pursued outside of the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Dose intensification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8828993\">",
"    <span class=\"h2\">",
"     Treatment at progression",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with advanced or metastatic soft tissue sarcoma (other than liposarcoma or gastrointestinal stromal tumor [GIST]) who progress after an anthracycline-containing regimen, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8828453\">",
"       'Pazopanib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where commercially available (in virtually all countries except the United States, Brazil, and Australia),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      is a reasonable treatment for leiomyosarcomas and liposarcomas that have failed standard anthracycline or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      based therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Trabectedin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/1\">",
"      Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 1999; 229:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/2\">",
"      Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985; 3:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/3\">",
"      Pearlstone DB, Pisters PW, Bold RJ, et al. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 1999; 85:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/4\">",
"      Spillane AJ, Fisher C, Thomas JM. Myxoid liposarcoma--the frequency and the natural history of nonpulmonary soft tissue metastases. Ann Surg Oncol 1999; 6:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/5\">",
"      Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/6\">",
"      Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/7\">",
"      Vogt-Moykopf I, B&uuml;lzebruck H, Merkle NM, Probst G. Results of surgical treatment of pulmonary metastases. Eur J Cardiothorac Surg 1988; 2:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/8\">",
"      Choong PF, Pritchard DJ, Rock MG, et al. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand 1995; 66:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/9\">",
"      Karavasilis V, Seddon BM, Ashley S, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/10\">",
"      Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol 1997; 15:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/11\">",
"      Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/12\">",
"      Spillane AJ, A'Hern R, Judson IR, et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000; 18:3794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/13\">",
"      Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/14\">",
"      Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/15\">",
"      Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 2011; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/16\">",
"      George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/17\">",
"      Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol 2010; 21:1130.",
"     </a>",
"    </li>",
"    <li>",
"     Palassini E, Stachiotti S, Negri T, et al. Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS) (abstract #10014). J Clin Oncol 2010; 28:701s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/19\">",
"      Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012; 23:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/20\">",
"      Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/21\">",
"      Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/22\">",
"      Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/23\">",
"      Taill&eacute; C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007; 146:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/24\">",
"      Dickson MA, Schwartz GK, Antonescu CR, et al. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer 2013; 132:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/25\">",
"      Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/26\">",
"      Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012; 118:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/27\">",
"      Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975; 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/28\">",
"      Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/29\">",
"      Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/30\">",
"      Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/31\">",
"      Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/32\">",
"      Borden EC, Amato DA, Edmonson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990; 66:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/33\">",
"      Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987; 23:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/34\">",
"      Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/35\">",
"      Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/36\">",
"      Casper ES, Schwartz GK, Sugarman A, et al. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 1997; 15:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/37\">",
"      Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/38\">",
"      Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/39\">",
"      Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 2009; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/40\">",
"      Eiling S, Lischner S, Busch JO, et al. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 2002; 147:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/41\">",
"      Wollina U, Hansel G, Sch&ouml;nlebe J, et al. Cutaneous angiosarcoma is a rare aggressive malignant vascular tumour of the skin. J Eur Acad Dermatol Venereol 2011; 25:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/42\">",
"      Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/43\">",
"      Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol 1997; 24:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/44\">",
"      Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993; 31 Suppl 2:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/45\">",
"      Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 7:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/46\">",
"      Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/47\">",
"      Cerny T, Leyvraz S, von Briel T, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999; 10:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/48\">",
"      Buesa JM, L&oacute;pez-Pousa A, Mart&iacute;n J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998; 9:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/49\">",
"      Sutton G, Blessing JA, Park R, et al. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 1996; 87:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/50\">",
"      van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 38:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/51\">",
"      Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997; 8:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/52\">",
"      Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13:1600.",
"     </a>",
"    </li>",
"    <li>",
"     Rahal AS, et al. High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. J Clin Oncol 30, 2012 (suppl; abstr 10044). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=95524 (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/54\">",
"      Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/55\">",
"      Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/56\">",
"      Nagano T, Yamada Y, Ikeda T, et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007; 110:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/57\">",
"      Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26:5269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/58\">",
"      Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/59\">",
"      Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/60\">",
"      Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol 2010; 11:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/61\">",
"      Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012; 118:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/62\">",
"      Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002; 94:3263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/63\">",
"      Anderson SE, Keohan ML, D'Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006; 2006:15947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/64\">",
"      Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/65\">",
"      Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976; 60:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/66\">",
"      Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991; 2:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/67\">",
"      Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/68\">",
"      Zucali PA, Bertuzzi A, Parra HJ, et al. The \"old drug\" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs 2008; 26:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/69\">",
"      Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991; 9:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/70\">",
"      Goldstein D, Cheuvart B, Trump DL, et al. Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990; 13:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/71\">",
"      Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/72\">",
"      Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/73\">",
"      Hartmann JT, Oechsle K, Huober J, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/74\">",
"      Ferraresi V, Ciccarese M, Cercato MC, et al. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 2008; 63:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/75\">",
"      Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/76\">",
"      Von Burton G, Rankin C, Zalupski MM, et al. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 2006; 29:59.",
"     </a>",
"    </li>",
"    <li>",
"     Duffaud F, et al. A FNCLCC French Sarcoma Group (GETO) multicenter randomized phase II study of gemcitabine versus gemcitabine and docetaxel in patinets with metastatic or relapsed leiomyosarcoma (LMS) (abstract). J Clin Oncol 2008; 26:555s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/78\">",
"      Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 2012; 23:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/79\">",
"      Bramwell VH, Eisenhauer EA, Blackstein M, et al. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/80\">",
"      Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/81\">",
"      Worden FP, Taylor JM, Biermann JS, et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005; 23:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/82\">",
"      Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/83\">",
"      Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998; 82:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/84\">",
"      Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/85\">",
"      Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/86\">",
"      Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/87\">",
"      Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007; 109:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/88\">",
"      Saeter G, Talle K, Solheim OP. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol 1995; 36:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/89\">",
"      Palumbo R, Palmeri S, Gatti C, et al. Combination chemotherapy using vincristine, adriamycin, cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) for advanced soft tissue sarcomas: a phase II study. Oncol Rep 1998; 5:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/90\">",
"      Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/91\">",
"      Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/92\">",
"      Siehl JM, Thiel E, Schmittel A, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 2005; 104:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/93\">",
"      Subramanian S, Wiltshaw E. Chemotherapy of sarcoma. A comparison of three regimens. Lancet 1978; 1:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/94\">",
"      Edmonson JH, Long HJ, Kvols LK, et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol 1997; 8:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/95\">",
"      Jeli S, Kovcin V, Milanovi N, et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997; 33:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/96\">",
"      Maurel J, L&oacute;pez-Pousa A, de Las Pe&ntilde;as R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 2009; 27:1893.",
"     </a>",
"    </li>",
"    <li>",
"     van der Graaf WTA, Judson I, Verweij J, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first-line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study of the EORTC Soft Tissue Sarcoma Group (late-breaking abstract 7). Data presented at the 2012 European Society of Medical Oncology (ESMO) Congress, Vienna Austria, September 28-October 2, 2012. file://abstracts.webges.com/myitinerary/author.html (Accessed on January 18, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/98\">",
"      Bramwell VH, Anderson D, Charette ML, Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; :CD003293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/99\">",
"      Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/100\">",
"      Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/101\">",
"      Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/102\">",
"      Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/103\">",
"      Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/104\">",
"      Penel N, Glabbeke MV, Mathoulin-Pelissier S, et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer 2011; 104:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/105\">",
"      Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012; 17:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/106\">",
"      Baker LH, Crowley JJ, Maki RG. Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). Oncologist 2012; 17:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/107\">",
"      Garc&iacute;a-Del-Muro X, L&oacute;pez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/108\">",
"      Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/109\">",
"      Palumbo R, Neumaier C, Cosso M, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 1999; 35:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/110\">",
"      Reichardt P, Tilgner J, Hohenberger P, D&ouml;rken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; 16:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/111\">",
"      Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/112\">",
"      Serrone L, Zeuli M, Gamucci T, et al. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol 2001; 47:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/113\">",
"      Fayette J, Penel N, Chevreau C, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs 2009; 27:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/114\">",
"      Schlemmer M, Wendtner CM, Falk M, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006; 71:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/115\">",
"      Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/116\">",
"      Blay JY, Bouhour D, Ray-Coquard I, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18:3643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/117\">",
"      Boulad F, Kernan NA, LaQuaglia MP, et al. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/118\">",
"      Kasper B, Scharrenbroich I, Schmitt T, et al. Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant 2010; 45:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/119\">",
"      Verma S, Younus J, Stys-Norman D, et al. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer 2008; 112:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/120\">",
"      Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol 2012; 23:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/121\">",
"      Herrero AB, Mart&iacute;n-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66:8155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/122\">",
"      Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol 2001; 19:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/123\">",
"      Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/124\">",
"      Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/125\">",
"      Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/126\">",
"      Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013; 13:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/127\">",
"      Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/128\">",
"      Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/129\">",
"      Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/130\">",
"      Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/131\">",
"      Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/132\">",
"      Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/133\">",
"      Theman TA, Hartzell TL, Sinha I, et al. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2009; 27:e198.",
"     </a>",
"    </li>",
"    <li>",
"     Trial information available online at file://clinicaltrials.gov/ct2/show/NCT01343277?term=trabectedin&amp;rank=9 (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     Groso F, Forni C, Frapolli R, et al. Sensitivity of myxoid round-cell liposarcoma to trabectidin may be related to a direct effect on the fusion transcript (abstract). J Clin Oncol 2007; 25:545s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/136\">",
"      Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/137\">",
"      Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009; 27:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/138\">",
"      Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/139\">",
"      van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.",
"     </a>",
"    </li>",
"    <li>",
"     Van Der Graaf W, Blay JY, Chawla SP, et al. PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized, double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. J Clin Oncol 30, 2012 (Suppl; abstr 10009). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=97682 (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/141\">",
"      D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/142\">",
"      Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/143\">",
"      Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/144\">",
"      von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012; 118:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/145\">",
"      Tariq Mahmood S, Agresta S, Vigil CE, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 2011; 129:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/146\">",
"      Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/147\">",
"      Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/148\">",
"      Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/149\">",
"      Debrock G, Vanhentenrijk V, Sciot R, et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/150\">",
"      Rhomberg W, Wink A, Pokrajac B, et al. Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation. Int J Radiat Oncol Biol Phys 2009; 74:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/151\">",
"      Jimenez RE, Zalupski MM, Frank JJ, et al. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 1999; 86:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/152\">",
"      Komdeur R, Plaat BE, van der Graaf WT, et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003; 39:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/153\">",
"      Abolhoda A, Wilson AE, Ross H, et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999; 5:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/154\">",
"      Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/155\">",
"      Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/11/41146/abstract/156\">",
"      Leahy M, Ray-Coquard I, Verweij J, et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007; 43:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7743 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41146=[""].join("\n");
var outline_f40_11_41146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Natural history of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histologic subtype and response to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      End points to define clinical benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pegylated liposomal doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Epirubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Taxanes and angiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gemcitabine and other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Doxorubicin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Combination versus single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Gemcitabine-based combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1458931\">",
"      Gemcitabine plus docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2793077\">",
"      Gemcitabine plus dacarbazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1458950\">",
"      Gemcitabine plus vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dose intensification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Growth factor support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stem cell support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEW TREATMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Trabectedin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antiangiogenic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8828453\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8828792\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8828676\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Differentiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Modifying resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bendamustine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Brostallicin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Choice of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8828993\">",
"      Treatment at progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/21/21854\" title=\"table 1\">",
"      Combination chemotherapy STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/54/38766\" title=\"table 2\">",
"      AIM 60_6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/20/41294\" title=\"table 3\">",
"      AIM 75_9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/42/2735\" title=\"table 4\">",
"      AIM 75_10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/6/25710\" title=\"table 5\">",
"      Gem plus doc for advanced sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=related_link\">",
"      Desmoid tumors: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14806?source=related_link\">",
"      Ifosfamide nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=related_link\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7410?source=related_link\">",
"      Treatment protocols for soft tissue and bone sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_11_41147="Empirical dosing of emergency antidotes";
var content_f40_11_41147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empirical dosing of emergency antidotes to adult patients in extremis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Suspected toxin (or similar agent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antidote",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanide",
"       </td>",
"       <td>",
"        5 g hydroxocobalamin IV, repeat x 1 (alternative is nitrite/thiosulfate kit)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"       <td>",
"        2 mL/kg 2 percent methylene blue IV over 5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        2 to 5 vials digoxin antibody (Fab) fragments IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blocker",
"       </td>",
"       <td>",
"        20 mL 10 percent calcium chloride IV, repeat x 2; 0.5 to 1 units/kg/hour insulin (and dextrose) IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local anesthetic",
"       </td>",
"       <td>",
"        1.5 mL/kg of 20 percent intralipid bolus IV, may repeat several times (alternatively, after bolus infuse 0.25 mL/kg per minute for 30 minutes; maximum dose 10 mL/kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium channel blockade",
"       </td>",
"       <td>",
"        100 mL of 7.5 percent to 8.4 percent sodium bicarbonate IV, repeat x 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholinergic agent",
"       </td>",
"       <td>",
"        2 mg atropine IV , doubled every 3 minutes as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"       <td>",
"        5 g pyridoxine over 10 minutes or until seizures stop; remainder over 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine",
"       </td>",
"       <td>",
"        2 mg/kg diazepam IV over 30 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional details about antidotes and further treatment of the poisons listed in this table can be found in the specific reviews discussing these poisonings.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41147=[""].join("\n");
var outline_f40_11_41147=null;
var title_f40_11_41148="Exposures associated with ILD";
var content_f40_11_41148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupational and environmental exposures associated with interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhaled inorganic dust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Silicates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silica (\"silicosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asbestos (\"asbestosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Talc (hydrated Mg silicates; \"talcosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kaolin or \"china clay\" (hydrated aluminum silicate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diatomaceous earth (Fuller's earth, aluminum silicate",
"with Fe and Mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nepheline (hard rock containing mixed silicates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aluminum silicates (sericite, sillimanite, zeolite)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Portland cement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mica (principally K and Mg aluminum silicates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beryllium (\"berylliosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Carbon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coal dust (\"coal worker's pneumoconiosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Graphite (\"carbon pneumoconiosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tin (\"stannosis\")&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Aluminum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Powdered aluminum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bauxite (aluminum oxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hard metal dusts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cadmium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Titanium oxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tungsten",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hafnium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Niobium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cobalt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vanadium carbides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron (\"siderosis\", \"arc welder's lung\") Barium (powder",
"of baryte or BaSO4; \"baritosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimony (oxides and alloys)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematite (mixed dusts of iron oxide, silica and",
"silicates; \"siderosilicosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed dusts of silver and iron oxide",
"(\"argyrosiderosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CuSO4 neutralized with hydrated lime (Bordeaux mixture;",
"\"vineyard sprayer's lung\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare earths (cerium, scandium, yttrium, lanthanum)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Crystal, RG. Interstitial lung disease. In: Wyngaarden, JB, Smith, LH, Jr, Bennett, JC, (Eds), Cecil Textbook of Medicine, 19th ed, WB Saunders Co, Philadelphia, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41148=[""].join("\n");
var outline_f40_11_41148=null;
var title_f40_11_41149="Contents: Hospital allergy and immunology";
var content_f40_11_41149=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital allergy and immunology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital allergy and immunology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/29/35290\">",
"           Anaphylaxis: Rapid recognition and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/11/1210\">",
"           Drug allergy: Classification and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/13/1241\">",
"           Fatal anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/54/40809\">",
"           Laboratory tests to support the clinical diagnosis of anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/35/9785\">",
"           Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/8/40070\">",
"           Latex allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/19/15672\">",
"           Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/51/42809\">",
"           Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/27/442\">",
"           Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/40/8842\">",
"           Serum sickness and serum sickness-like reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/59/1978\">",
"           Vancomycin hypersensitivity",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-733E368BE6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_11_41149=[""].join("\n");
var outline_f40_11_41149=null;
var title_f40_11_41150="Sphincter of Oddi algorithm";
var content_f40_11_41150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Approach to suspected sphincter of Oddi dysfunction (Milwaukee class III)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 531px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SO: sphincter of Oddi.",
"     <br>",
"      * Assumes SO intact.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41150=[""].join("\n");
var outline_f40_11_41150=null;
var title_f40_11_41151="Thyroid hormone action part A";
var content_f40_11_41151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62658%7EENDO%2F75347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62658%7EENDO%2F75347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Mediation of thyroid hormone action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 205px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the absence of T3, thyroid hormone receptor (TR) heterodimerizes with retinoid X receptor (RXR), binds to a thyroid hormone response element (TRE) and recruits co-repressor (CoR), resulting in gene silencing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Mediation of thyroid hormone action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Binding of T3 disrupts binding of co-repressor (CoR) to the thyroid hormone receptor (TR) retinoid X receptor (RXR) heterodimer, promotes binding of co-activator (CoA), and increases mRNA expression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_11_41151=[""].join("\n");
var outline_f40_11_41151=null;
